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ABSTRACT OF THE DISSERTATION 
INTERACTION OF HIGH MOLECULAR WEIGHT COMPOUNDS WITH α, β-
UNSATURATED CARBONYL MOIETY WITH MAMMALIAN AND DROSOPHILA 
MELANOGASTER THIOREDOXIN REDUCTASE 
by 
Anupama Tuladhar 
Florida International University, 2018 
Miami, Florida 
Professor Kathleen Rein, Major Professor 
The thioredoxin system is the major cellular reductant system present in the cell, 
whose role is to maintain cellular redox homeostasis. It does this in part, by regulating the 
activity of many other enzymes including ribonucleotide reductase, which is essential for 
DNA synthesis. It also acts as an antioxidant, reducing destructive reactive oxygen 
species. The thioredoxin system is comprised of thioredoxin (Trx) which reduces target 
protein disulfide bridges by thiol-disulfide exchange and thioredoxin reductase (TrxR) 
which reduces Trx back to its active state. Thioredoxin reductase is a common target for 
many cancer drugs including cisplatin and auranofin. Recently we have shown that the 
Florida red tide toxin, brevetoxin-2 (PbTx-2) can inhibit mammalian TrxR1. Brevetoxin-
2 has α, β-unsaturated aldehyde moiety that was proposed to inhibit the enzyme by 
forming a Michael adduct. Several compounds which are similar to brevetoxin in size and 
functionality have a similar effect on TrxR. These compounds include antitumor and 
antibiotics such as manumycin A, geldanamycin, rifamycin SV and thiostrepton and 
toxins such as brevetoxin-3, nodularin and microcystin-LR. Manumycin A behaves as a 
vii 
typical TrxR1 inhibitor while other compounds screened activate the reduction of small 
disulfides such as DTNB (5,5’-dithiobis-(2-nitrobenzoic acid)). Mammalian thioredoxin 
reductase is a homodimer with two redox center viz. N-terminal dithiol buried in the 
enzyme and C-terminal selenosulfide located on the flexible C-terminal tail. Modification 
of the C-terminal tail of TrxR by these test compounds can expose N-terminal redox thiol 
that could reduce DTNB. The C-terminal Sec, a nucleophile can form a Michael adduct 
with α, β-unsaturated carbonyl moiety of test compounds. Together with point-specific 
mutant enzymes (C-terminal tail truncated, dead tail and Cys mutant) and enzyme assays 
that are specific/dependent on C-terminal Sec were used to decipher the site-specific 
interaction between these test compounds and TrxR. Inhibition of TrxR at the C-terminal 
redox center produces a pro-oxidant known as SecTRAP (Selenium Compromised 
Thioredoxin Reductase-derived Apoptotic Proteins), which uses NADPH to produce 
superoxide radical anion as observed with manumycin A. Since many cancer drugs target 
TrxR the present study has the potential to discover new cancer drugs. 
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Chapter 1. Introduction 
 
 Cellular homeostasis in mammalian cells is maintained principally by two redox 
enzymes viz. glutathione reductase (GR) and thioredoxin reductase (TrxR). These two 
enzymes share structural, functional and mechanistic similarities. Both utilize cysteines at 
the active site, reducing their substrates by thiol-disulfide exchange.  The principle role of 
GR is the reduction of the disulfide bond of oxidized glutathione while TrxR reduces 
thioredoxin (Trx). In turn, thioredoxin (Trx) reduces protein disulfide bridges of 
numerous protein targets. 
The pKa of cysteine is modulated by environment such as hydrogen bonding, co-
ordinating metal ion or the helix dipole1. Under physiological conditions the pKa of 
cysteine (Figure 1) can be lowered significantly, which makes cysteine an ideal electron 
donor to the oxidized proteins. In addition to S, another group 6 element Se, is 
incorporated into the 21st amino acid, as selenocysteine (Figure 1) (Sec). While 
selenoproteins are rare, they are present in a wide variety of organisms from mammals to 
protists. Selenium (Se) is a rare non-metal that was discovered by Swedish chemist Jöns 
Jacob Berzelius in 1817. It is believed that the presence of Se in the enzyme active site 
imparts increased reactivity as well as a broad substrate range. Mammalian 
selenoproteins include thioredoxin reductase (TrxR), glutathione peroxidase (GPxs), 
iodothyronine deiodinase, methionine sulfoxide reductase 1B, selenophosphate 
synthetase 2 and selenoprotein P. Beside proteins, mammalian and bacterial tRNA 
(transfer ribonucleic acid) also contain selenium.   
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  Cysteine (Cys)                                    Selenocysteine (Sec) 
Figure 1.  Amino acids 
 Mammals have three different isoforms of TrxR: cytosolic represented as TrxR1, 
mitochondrial represented as TrxR2 and testis specific TrxR represented as thioredoxin 
glutathione reductase (TGR). Thioredoxin reductase regulates many cellular processes by 
reducing Trx and is required for the normal development of the embryo. Deletion of TrxR 
and the Trx gene has different impacts on developing embryos. Mitochondrial TrxR and 
Trx are highly expressed in metabolically active tissues such as heart, kidney and liver2 to 
prevent oxidative stress and is essential for the survival of mice embryos. The deletion 
of the TrxR2 gene is associated with hematopoiesis, heart dysfunction and apoptosis3, a 
condition similar to Keshan disease, which is related to a deficiency of Se in the diet. On 
the other hand, TrxR1 knockout mice embryos show retarded growth with reduced cell 
proliferation followed by death of the embryo without affecting the heart4. Thioredoxin 
glutathione reductase which reduces both glutathione as well as thioredoxin is 
specifically required during spermatogenesis. However, knockdown of the TGR gene is 
associated with decreased transcriptional activity of retinoic acid receptor (RAR) in mice 
that mediates biological processes such as cell proliferation, differentiation and 
development through retinoic acid5. 
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1.1 The thioredoxin system 
 
 The thioredoxin system consists of TrxR, Trx, NADPH and FAD where TrxR 
reduces oxidized Trx in an NADPH dependent reaction, as shown in Figure 2. The 
reduced Trx in turn reduces targets such as insulin, ribonucleotide reductase and 
transcriptional factors6. Thioredoxin reductase belongs to the family of pyridine 
nucleotide disulfide oxidoreductases, which also includes other enzymes such as 
glutathione reductase, mercuric ion reductase and lipoamide dehydrogenase. Other roles 
of TrxR include antioxidant defense, cellular proliferation, DNA and protein repair, 
transcription of protein and its folding. 
  
Figure 2. Electron flow of the thioredoxin system. Trx reduces many proteins and is returned to 
the active reduced state by TrxR in a NADPH dependent reaction 
 
 Thioredoxin reductase is present in all living organisms and has evolved 
significantly, with numerous homologs identified7. Thioredoxin reductase homologs 
differ in size and the number and sequence of redox centers.  These variations form the 
basis of the classification systems. Thioredoxin reductases from lower eukaryotes and 
prokaryotes are low-Mr dimers of ~35 kDa subunits that utilize two redox centers: a non-
covalently bound FAD and a N-terminal dithiol/disulfide (Cys-Ala-Thr-Cys). The two 
redox centers are juxtaposed in the oxidized form but when reduced, the N-terminal 
dithiol rotates to expose the dithiol towards the solvent surface facilitating reduction of 
Trx8. The oxidized disulfide then rotates to its original position to be reduced by FAD. 
NADP+
NADPH + H+
TrxRox
TrxRred
Trxox
Protein-SH2
Protein-S2
Trxred
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The high-Mr TrxR (present in numerous animals, including vertebrates, 
invertebrates, insects and protists) are composed of two monomers aligned antiparallel to 
each other. This class of TrxR has an additional C-terminal redox center, not present in 
the low-Mr enzymes, whose sequence varies according to the source. The C-terminal tail 
of higher eukaryotes is highly conserved and flexible with variable redox sites. 
Mammalian TrxR is composed of two high molecular weight (Mr ~55 kDa) subunits 
arranged such that the reducing equivalent of NADPH is transferred via the N-terminal 
dithiol to the C-terminal redox center of the other monomer, as shown in Figure 3. 
 
 
Figure 3. Electron flow from NADPH to protein disulfide bridges, via TrxR and Trx. (A) 
Prokaryotic, low-Mr TrxR. (B) High Mr TrxR. The C-terminal redox center in high Mr TrxR can 
be composed of either 2 cysteines residues or a cysteine and a selenocysteine 
 
 Thioredoxin reductase from higher organisms can be further classified into two 
groups on the basis of the sequence of the C-terminal redox center. Type I TrxR, with a 
vicinal selenosulfide bond (X-Cys-Sec-X) sequence is present in animals or vicinal 
disulfide bond (X-Cys-Cys-X) as in Drosophilia melanogaster. Mammals have a 16 
amino acid C-terminal tail which helps to shuttle electrons received from the N-terminal 
dithiol to the target protein. Type II TrxR have redox cysteines separated as in 
Plasmodium falciparum (Cys-Gly-Gly-Gly-Lys-Cys-Gly). Detailed classification of the 
A
NADPH + H +
NADP+ FAD
FADH2 TrxR-(SH)2
Trx-S2
Trx-(SH)2
Protein-S2
Protein-(SH)2
TrxR-S2
NADPH + H +
NADP+ FAD
FADH2
S-S/Se
I    I
TrxR
TrxR
I      I
SH  S/ Se-
Trx-S2
Trx-(SH)2
Protein-S2
Protein-(SH)2
B
TrxR-(SH)2
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C-terminal redox centers is presented in Table 1. Despite the disparity in the C-terminal 
redox center these TrxR share some identities and have similar mechanism of action.Table 
2 displays the sequence identity of various large Mr TrxR.  
                   Table 1. Classification of TrxR on the basis of C-terminal redox center 
 
 Species C-terminal motif 
Type I 
Human/Rat TrxR -GCUG(Cytosolic/Mitochondrial) 
Caenorhabditis elegans 
-GCUG (Cytosolic) 
-GCCG (Mitochondrial) 
Drosophila melanogaster -SCCS (Cytosolic/Mitochondrial) 
Type II Plasmodium falciparum -CGGGKCG 
 
 
Table 2. Sequence identities of various large Mr TrxR. Identities were determined using Clustal 
Omega multiple sequence alignment software9 
 
 Accession 
number 
Plasmodium 
falciparum 
Drosophila 
melanogaster 
Caenorhabdit
is elegans 
Homo 
sapiens 
Plasmodium 
falciparum 
CAA60574.1 100 46.25 44.98 46.41 
Drosophila 
melanogaster 
NP_524216.1 46.25 100 43.97 50.81 
Caenorhabdit
is elegans 
NP_0012937
61.1 
44.98 43.97 100 58.38 
Homo 
sapiens 
AAB35418.1 46.41 50.81 58.38 100 
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1.2 Biosynthesis of selenoproteins in mammalian TrxR 
 
 In humans, three genes TXNRD1, TXNRD2 and TXNRD3 encode for TrxR1, 
TrxR2 and TGR respectively. The TXNRD1 gene is located on the chromosome 12q23.3 
and the cDNA sequence has 3826 bp which encodes for 495 amino acids. The human 
TXNRD1 gene is divided into 16 exons including 100 kb DNA10. The human 
mitochondrial TXNRD2 gene is localized in chromosomal position 22q11.2 and consists 
of 18 exons with 67 kb DNA11. It has 521 amino acid residues with a molecular mass of 
56.2 kDa. The TXNRD3 gene is localized in chromosomal position 22q11.2 and has 65 
kilobases in humans12. 
 The C-terminal tail of mammalian TrxR is highly conserved among mammals 
with the sequence –Gly-Cys-Sec-Gly. The selenium of the Sec residue is derived from 
hydrogen selenide in a reaction catalyzed by selenophosphate synthesase2 in all 
eukarya/archaea and bacteria.  Selenocysteine is encoded by TGA in the sequence GGC 
TGC TGA GGT TAA. The stop codon is normally encoded by TGA but here TAA is the 
true stop codon. The incorporation of Sec into selenoproteins requires recoding of the 
TGA which is accomplished by SECIS (Selenocysteine Insertion Sequence) element 
located at the 3’-untranslated region (3’-UTR) of the mRNA. The SECIS element forms a 
stem loop structure that guides a special tRNA to insert Sec into the growing peptide 
rather than to read it as termination codon.  
The mechanism of Sec insertion in proteins differs between bacteria, archaea and 
higher eukaryotes. In eukaryotes selenoprotein synthesis requires a Sec specific tRNA 
(tRNAsec) which plays the vital role in Sec incorporation into proteins. It begins with 
aminoacetylation of tRNAsec by serine, the process is catalyzed by seryl-tRNA synthetase 
  7 
(SerRS). The serine hydroxyl is phosphorylated by O-phosphoseryl-tRNA kinase (PSTK) 
in eukarya and archaea. The enzyme Sep-tRNA:Sec-tRNA synthase (SepSecS) converts 
O-phosphoseryl-tRNA to selenocysteinyl-tRNAsec by substitution of the phosphate group 
with selenophosphate13.  
Four genes are involved in incorporation of Sec in bacterial selenoproteins: selA, 
selB, selC and selD. The gene selC codes for tRNAsec 14 that accepts serine at the 
beginning and co-translationally inserts Sec in the reaction catalyzed by Sec synthase 
(product of SelA genes)15. The conversion of ser-tRNAsec into sec-tRNAsec is catalyzed by 
Sec synthase where selenium is donated by selenophosphate. Selenophosphate 
synthetase, a product of selD gene catalyzes the reaction that converts the selenide to 
selenophosphate by the consumption of ATP16.  
 The sec-tRNAsec has the anticodon ACU which reads the UGA code (also a stop 
codon) in mRNA and co-translationally inserts Sec into the growing polypeptide chain in 
the presence of the SECIS element which is located after the stop codon in eukaryotes 
and before the stop codon in bacteria. The SECIS binding protein (SBP2) binds to the 
SECIS element of mRNA and along with elongation factor (EF) translates the code UGA 
to Sec.  In bacteria, selB, a selenocysteine specific translational elongation factor and also 
homolgous to SBP2 in eukaryotes directly binds to SECIS and translates for Sec. The 
mechanism of Sec insertion is shown in Figure 4. 
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Figure 4. Insertion of Sec in eukaryotes and bacterial protein. (A) Incorporation of Sec in tRNA 
in eukaryotes and bacteria begins with attachment of L-serine to tRNA. The seryl group is 
phosphorylated by kinase phosphoseryl-tRNA kinase (PSTK) to O-phosphoseryl-tRNA. 
Selenophosphate synthase (SPS2) and SepSecS incorporates Sec in tRNA, sec-tRNAsec. In 
bacteria, selA and selD catalyzes the conversion of Ser-tRNAsec to Sec-tRNAsec (B) Translation 
of mRNA to protein in eukaryotes. The sec-tRNAsec is transported to ribosome by an elongation 
factor at the codon UGA and SECIS binding protein (SBP2) specifically binds to SECIS element 
which recognizes UGA as a code for Sec and incorporates in a growing polypeptide. In bacteria, 
direct binding of SelB to SECIS codes for Sec. Adapted from reference 16 
 
1.3 Catalytic properties of mammalian TrxR 
 
Thioredoxin reductase is a homodimer flavoenzyme whose monomers are aligned 
in an antiparallel arrangement. The FAD is located in close proximity to the N-terminal 
redox center, which is comprised of Cys59 and Cys64 in human’s TrxR1. In addition to the 
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N-terminal redox center the human TrxR has a C-terminal redox center which is 
comprised of Cys497 and Sec498. The catalytic cycle of mammalian TrxR begins by 
transfer of two electrons to FAD by oxidation of one equivalent of NADPH. The reduced 
FAD (FADH2) forms a charge transfer complex with Cys64. As shown in Figure 5, the 
base His472 abstracts the proton from Cys59. This reaction is thermodynamically favoured 
by -2.2 kcal/mol due to the presence of proton acceptor Glu477 which stabilizes the 
imidazole ring17. The importance of catalytic triad (His472, Glu477 and Cys59) is also 
supported experimentally where mutation of Glu477 to Lys, Ala or Gln decreases the 
enzymatic activity significantly (nearly 6-15 folds)18. The reduced Cys59 reduces the 
selenosulfide (Cys497- Sec498) redox site located at C-terminal tail. The new selenosulfide 
bond between (Cys59- Sec498) is then reduced by Cys64. Once reduced the C-terminal 
redox center swings out of the pocket to reduce substrate19.The oxidized C-terminal tail 
then enters a tetra peptide (Gly-Cys-Sec-Gly) pocket, a narrow groove and is reduced by 
the N-terminal redox center. The mammalian TrxR utilizes Sec as the formation of 
selenoate in comparison to thiolate is thermodynamically favoured by additional -2.3 
kcal/mol due to second catalytic triad (His472, Glu477 and Sec498)17. 
As compared to mammalian TrxR, DmTrxR is a homodimeric with the C-terminal 
redox center (-Ser-Cys-Cys-Ser). The mechanism of reduction is similar to mammalian 
TrxR, as shown in Figure 5. However, DmTrxR does not have Sec at C-terminal but 
rather uses cysteine to reduce the substrates. The reduction cycle starts by reduction of 
the N-terminal disulfide by the reducing equivalent obtained from the oxidation of 
NADPH20. This catalytic process of mammalian TrxR is known as a ping pong 
mechanism, as illustrated in Figure 5. 
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 The mammalian TrxRs have wide substrate tolerance which is attributed to the 
presence of Sec. It is known to reduce Trx of other species such as E. coli as well as other 
substrates such as the diselenide selenocystine, DTNB, lipoic acid and juglone. Although 
the functional C-terminal tail is required for the reduction of most of the substrates, some 
small molecules such as DTNB and selenite have been reported to be reduced by the N-
terminal redox center as well. 
 
Figure 5. Catalytic cycle of mammalian (M) and Drosophila melanogaster (D) TrxR. DmTrxR 
X= Cys, mammalian TrxR X= Sec. All the reduced moieties are shown in red. Step 1: FAD is 
reduced by NADPH forming EH2. Step 2: (FADH2) forms a charge transfer complex with 
C64M/C62D and transfers two electrons to C59M/C57D, reducing the disulfide bond. Step 3: The 
histidine from catalytic triad abstract the hydrogen from C59M/C57D. Step 4: A pair of electrons 
moves to X from C59M/C57D, reducing the selenosulfide bond. Step 5: Second equivalent of 
NADPH reduces FAD. Step 6: C-terminal selenocysteine is oriented towards solvent surface to 
reduce substrates and cycle returns to Step 1. Adapted from reference 19 
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1.4 Importance of Sec in mammalian TrxR 
 
 Selenium (Se) is an essential micronutrient, but an excess dose can cause 
selenium poisoning with symptoms including diarrhea, hair loss, nail discoloration and 
brittleness, nausea, muscle pain and cramps. The recommended daily intake for Se is 55 
μg/day for adults21. On the other hand, selenium deficiency is associated with Keshan 
disease characterized by myocardial necrosis and Kashin-Beck disease characterized by 
necrosis of cartilage tissue22 and hypothyroidism. The selenium containing enzyme 
iodothyronine deiodinase has an important role in conversion of thyroxine (T4) to 
triiodothyronine. About 25 human enzymes have Sec as an active electron donor which 
includes glutathione peroxidase, deiodinases, thioredoxin reductase, selenoprotein W, 
selenoprotein P, selenophophate synthatase and others23. It is intriguing why some 
enzymes use Sec while the other enzyme is less dependent on the use of Sec. One reason 
for an enzyme to replace sulfur with selenium is to achieve high efficiency in oxidizing 
conditions as the oxidation of selenium is reversible under physiological conditions, as 
shown in Figure 6 24. 
            
              
Figure 6. Comparison of reversible oxidation of selenide and sulfide 
 
All the three mammalian TrxR isoenzymes viz. TrxR1, TrxR2 and TGR 
(thioredoxin/glutathione reductase) are homologous. Figure 7 shows the comparison of 
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different domains of mammalian TrxR isoforms. The sequence identity among different 
mammalian TrxR isoforms are shown in Table 3 where mTrxR2, hTGR and mTrxR1 
represents mouse mitochondrial TrxR, human TGR and mouse cytoplasmic TrxR 
respectively. 
 
Figure 7. Comparison of different domains in glutaredoxin (Grx), glutathione reductase (GR), 
thioredoxin reductase (TrxR) and thioredoxin glutathione reductase (TGR). Thioredoxin 
reductase and TGR have N-terminal domain (CVNVGC) and C-terminal domain (GCUG) with a 
highly conserved redox site. These two domains are separated by the interface where two 
monomers interact. TGR has an extended portion with a sequence similar to Grx. Humans have 
single cysteine in Grx (Cys-Pro-His-Ser) while Schistosoma mansoni have a pair of cysteine 
(Cys-Pro-Tyr-Cys). Glutathione reductase on the other hand has only a single, N-terminal redox 
domain 
 
Table 3. Sequence identities of different mammalian TrxR isoforms 
 
 mTrxR2 hTGR mTrxR1 
mTrxR2 100 52 55.85 
hTGR 52 100 72.14 
mTrxR1 55.85 72.14 100 
 
Among these three types of mammalian TrxR, cytosolic TrxR1 is the most 
extensively studied and is known to have broad substrate acceptance and can reduce 
bacterial as well as human Trx. The cytosolic TrxR1 is highly dependent on C-terminal 
CVNVGC FAD NADPH Interface
CVNVGC FAD NADPH Interface GCUG
CVNVGC FAD NADPH Interface GCUGCPHS
GR
Mammalian TrxR
Human TGR
N-terminal domain C-terminal domain 
Grx CXXC
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Sec to reduce Trx. Mutation of the Sec to Cys decreases the enzyme activity by ~90 fold 
when human Trx is used as substrate25. On the other hand, mutation of Sec to Cys in 
TrxR2 shows no such profound decrease in activity when E. coli Trx is used as substrate. 
Such vast disparity between the two isoenzymes has been attributed to the guiding bar. 
The guiding bar is comprised of amino acids Trp407', Asn418' and Asn419' and forms the 
hydrogen bond to Gln494'-496' in hTrxR 26 which is present in the same monomer. The 
guiding bar restricts the random motion of the C-terminal arm in TrxR1 through 
hydrogen bonding which renders the TrxR1 to be dependent on the nucleophilicity of Sec 
to reduce substrates. Mutation of Sec to Cys which is less nucleophilic greatly 
compromises the enzyme activity. On the other hand, the absence of guiding bar in TrxR2 
allows the substrates to be reduced by both C-terminal as well as N-terminal redox center 
as the C-terminal tail is flexible.  
Thioredoxin glutathione reductase is 65 kDa subunit primarily expressed in male 
germ cells and catalyzes the disulfide bond formation during protein folding27. Beside 
spermatogenesis, TGR functions as a sole disulfide enzyme required for cell growth and 
immune response in the phylum Platyhelminthes where other isoforms of TrxR and GR 
are absent28. Structurally, TGR includes a glutaredoxin domain (Cys-X-X-Cys) at the N-
terminus. The catalytic mechanism of TGR is similar to other isoforms. However, 
because of the presence of the glutaredoxin domain; it can reduce both thioredoxin as 
well as glutathione as the name (TGR) suggests. The reduction of glutathione is carried 
out by the glutaredoxin domain which in turn is reduced by C-terminal selenothiol. 
 The broad substrate range of mammalian TrxR has been attributed to the presence 
of the nucleophilic Sec. Also, the low pKa ~5.6 of Sec ensures that the Sec is 
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deprotonated under normal physiological conditions imparting activity when compared to 
the Cys counterpart. However, as a result of the nucleophilic character of the Sec, 
mammalian TrxR is susceptible to inactivation by irreversible alkylation with numerous 
electrophiles.  
1.5 Role of TrxR in oxidative stress 
 
Reactive oxygen species (ROS) such as peroxide, are produced by cells in 
response to external (phagocytes) as well as internal (NADPH oxidase) stimuli. Cells 
produce ROS which act to regulate signal transduction under normal conditions. 
However, excess production of ROS leaves the cells under oxidative stress and is 
potentially a threat to cell survival. Hence, ROS are tightly regulated by 
antioxidants/ROS scavengers including the Trx and glutathione (GSH) systems. 
Thioredoxin in particular provides reducing equivalents to peroxiredoxin (Prx) that 
transfers the electrons to reduce H2O2 and ROOH to H2O/ROH29. Oxidation of 
methionine to methionine sulfoxide results in incorrect folding of protein such as E200K 
prion protein30 associated with Creutzfeldt-Jakob disease, a neurodegenerative disease. 
Similarly, other diseases related to misfolded proteins include Alzheimer’s, Huntington’s 
and Parkinson’s. The enzyme methionine sulfoxide reductase (Msr) corrects the 
misfolded protein through reduction of methionine sulfoxide in a stereospecific manner 
by receiving the reducing equivalent of electrons from Trx. The antioxidant property of 
the Trx system is shown in Figure 8.  
 Human primary cancerous cells, such as acute lymphoblastic leukemia31, lung32, 
cervix33 and liver34 are known to overexpress thioredoxin which helps these cells combat 
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ROS. The Trx system also regulates biological functions such as modulation of 
transcription factors, stimulation of cell growth and inhibition of apoptosis. Apoptosis 
signal-regulating kinase-1 (ASK-1) is arrested in its inactive form by reduced Trx by 
interacting with the N-terminal coiled domain of ASK-135-36. Under oxidative stress 
induced by ROS and tumor necrosis factor (TNF-α), oxidation of Trx stimulates ASK-1 
to signal apoptosis by activating the p53 and JNK MAPK pathway37. On the other hand, 
oxidative stress downregulates the expression of thioredoxin interacting protein (Txnip), 
which otherwise inhibits the activity of Trx and promotes cell growth and this promotes 
apoptosis in vascular endothelial cells38 and cardiomyocytes39. Several studies have 
shown that Trx is translocated into the nucleus under oxidative conditions. The nuclear 
Trx activates nuclear factor κB (NF-κB) transcriptional activities that controls gene 
expression. In the cytoplasm, NF-κB exists as heterotrimeric complex with inhibitor I-
κB. When I-κB dissociates under the influence of stimuli, the NF-κB migrates to the 
nucleus and promotes cancer growth40. Another transcription factor AP-1 (Activator 
protein 1), which regulates expression of genes involved in cell growth, is also indirectly 
activated by nuclear Trx via interaction with Ref-141 (redox factor 1), as shown in  
Figure 9. 
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Figure 8. Antioxidant properties of thioredoxin reductase. (A) Peroxidredoxin (Prx) scavenges 
peroxides such as H2O2, lipid peroxides (ROOH) and preoxynitrite (ONOO-). The C47 and C170 are 
highly conserved in Prx family and is the part of active catalysis. C47-SH is prone to oxidation by 
peroxides to C47-SOH so called peroxidatic C(Cp). The resolving C170 (CR) forms disulfide 
linkage with C47-S-S-C170 in yeast after oxidation. This disulfide bond is reduced by Trx which is 
reduced by TrxR in NADPH dependent reaction. (B) However, in eukaryotic Prx, cysteine 
sulfenic acid (C-SOH) is further oxidized into cysteine sulfinic acid (Cp-SOOH) which is then 
reduced by sulfiredoxin. (C) Catalytic mechanism of methionine sulfoxide reductases. The 
nucleophilic cysteine of Msr attacks the methionine sulfoxide to convert it to active methionine. 
The oxidized Msr reductase is then reduced by Trx system. Adapted from reference 29,30 
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Figure 9. Redox signaling of transcription factor by thioredoxin system in cells. Trx negatively 
regulates apoptosis by arresting ASK-1 in an inactive form. The oxidation of Trx releases ASK-1 
which induces apoptosis by activating p32 MAP kinase pathway. Under an oxidative stress Trx is 
translocated into nucleus where it reduces NF-κB and increases its DNA binding activity. Adapted 
from references 36,40 
 
1.6 Thioredoxin system in reference to cancer 
 
 All aerobic organisms produce ROS, a necessary evil which exists in internal 
balance with antioxidants. External and internal stimuli, shown in Figure 10, perturb the 
internal balance and promote ROS generation. These ROS include hydroxyl anion (OH-), 
superoxide anion (O2-.), hydrogen peroxide (H2O2) and nitric oxide (NO), primarily 
produced by inhibition of TrxR, NADPH oxidase in mitochondria as the result of cellular 
respiration. Superoxide and H2O2 function as the mediators of nuclear transcription 
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factors such as NF-κB and activator protein-1. Hydrogen peroxide activates redox 
sensitive kinases such as protein kinase B, protein kinase C, mitogen activated protein 
kinase and is also required for insulin and growth factor-induced tyrosine kinase 
signaling. To maintain the cellular homeostasis, an organism develops internal defense 
systems of antioxidants which fight off excess ROS. Reactive oxygen species in general 
are produced by normal cells, for transduction of signal, to regulate transcriptional factor 
and to fight phagocytic invasion. However, production of excess ROS becomes harmful 
to cells and can lead to oxidative stress, ultimately leading to mutagenesis and apoptosis. 
Study of different cancer cells, viz. cervical33, lung42, hepatoma43, squamous carcinoma 
cell44, pancreatic cancer cells45, all show elevated Trx-1. It is believed that the increased 
Trx activity helps cancer cells fight against ROS and decreases apoptosis. In order to 
fight cancer, the cellular defense mechanism continuously produces more antioxidants. 
The imbalance in ROS and antioxidants is the driving force for cancerous cells to thrive. 
The cells have two types of antioxidants: enzymes that the cells produce naturally and 
lower molecular weight antioxidants that can be externally supplemented. Both kinds of 
antioxidants act in a similar manner by scavenging ROS. The enzymes can continuously 
renew their redox property while lower molecular weight antioxidants need to be 
regulated via enzyme activity through redox reactions once the antioxidant is oxidized. 
Low molecular weight antioxidants such as vitamin C in human myeloid cells (HK-60)46, 
tocopherol in brine shrimp47,38, and the use of Trolox (6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid) a water-soluble vitamin E analog in mouse 
thymocytes48, have been reported to prevent oxidative stress induced apoptosis.  
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 Inhibition of the thioredoxin system has proven to be a successful approach to 
control cancerous cell growth. Several thioredoxin system inhibiting drugs, such as 
cisplatin, auranofin and others, have been approved by the FDA for cancer treatment and 
more drugs are continuously discovered. Most of these cancer drugs affect the C-terminal 
moiety of thioredoxin reductase inhibiting the enzymatic property and producing the 
oxidative milieu in cancerous cells. The inhibition of C-terminal moiety increases the   
ROS in many cellular processes described above, ultimately leading to apoptosis of 
cancerous cells.  
                     
    Figure 10. Sources of ROS 
1.7 Mammalian thioredoxin reductase and inhibitors  
 
The broad substrate tolerance of mammalian TrxR is believed to be due to the 
increased enzyme activity attributed to the presence of Sec. The reduced TrxR shuttles 
electrons through Trx to other substrates (Figure 11A). But mammalian TrxR alone can 
also reduce other substrates, as shown in Figure 11B. The activity of TrxR is inhibited by 
naturally occurring compounds curcumin (an important key constituent of turmeric and 
known to have antioxidant and anti-inflammatory property). In addition to organic 
inhibitors, some organometallic compounds also inhibit thioredoxin reductase. Known 
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TrxR inhibitors are listed in Table 4. Most of the known inhibitors interact with the C-
terminal Sec, covalently modifying the enzyme. However, some of the metal-based 
compounds may interact with TrxR in different way. The crystal structure of TGR and 
auranofin reveals the gold atom coordinated between N-terminal Cys154 and Cys159, 
Cys520 and Cys574 and NADPH binding pocket of Schistosoma mansoni TGR49. Cisplatin, 
a platinum compound, also interacts at the C-terminal Sec. At the same time, it is a DNA 
alkylator which interacts with nitrogen (N-7) of guanine base, unwinding the DNA helix 
through intra-strand crosslink50, leading ultimately to apoptosis as a result of DNA 
damage. Another derivative of cisplatin, 5-Nitro-2-furancarbohydrazide derivatives 
interact with Sec through cisplatin and N-terminal Cys through the nitrofuran moiety51.  
The organic inhibitors on the other hand, activate the NADPH oxidase activity of 
TrxR by inhibiting the C-terminal redox center. In the absence of functional or intact C-
terminal redox center, TrxR is converted to a pro-oxidant which causes the N-terminal 
redox center to oxidize NADPH to NADP+ and produce superoxide anion, as shown in 
equation below.  
 
Such a pro-oxidant enzyme is also called SecTRAP (selenium compromised 
thioredoxin reductase-derived apoptotic protein)52. The ROS produced as a result 
inactivates redox regulating enzymes. Thus, the oxidized environment inside the cell 
becomes lethal. Because of their TrxR inhibiting properties some compounds such as 
cisplatin are approved for the treatment of testicular and ovarian cancers53.  Many of 
these inhibitors are electrophiles and have α, β-unsaturated aldehyde or carbonyl group. 
 
NADPH H+ + 2O2
.- + NADP++ 2O2
TrxR
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Figure 11. Substrates for mammalian TrxR. (A) Substrates reduced indirectly via Trx (B) 
Substrates reduced directly by TrxR.    
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Table 4. Table of TrxR inhibitors 
 
Inhibitor type Enzymes IC50 Site of reaction 
Cisplatin 
Cisplatin derivative 5-Nitro-
2-furancarbohydrazides 
 
Human placental 
TrxR, induce 
NADPH oxidase, 
crosslink DNA, 
apoptosis 
~25 μΜ54 
16 μΜ42 
C497 and U498 
N-terminal C 
Auranofin 
 
Schistosoma 
mansoni TGR49 
 
Between C154 and  C159 
Between C520 and C574 
NADPH binding pocket 
Arsenic trioxide55 Human TrxR1 0.25 μM 
C497 and U498 
possibly N-terminal 
 
DNCB 
Human TrxR1, 
induce NADPH 
oxidase 
 
C497 and U498 
 
Juglone (5-Hydroxy-1,4-
napthoquinone) 
Inhibits TrxR, 
induce NADPH 
oxidase 
  
Curcumin56 
Rat TrxR1, NADPH 
oxidase activity, 
generates 
superoxide anion 
3.6 μM 
C497 and U498 
 
Μansonone F 
 
 
 
NADPH oxidase 
activity, generates 
superoxide anion 
5.2 ± 0.6 57  
Mercuric chloride 58 Inhibits TrxR 7.2 nM  
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Chapter 2. Objectives and Rationale 
 
2.1 Preliminary studies 
 
Karenia brevis, a dinoflagellate responsible for Florida red tide occurs 
ubiquitously in the Gulf of Mexico. It is well known for the production of neurotoxins 
known as brevetoxins (PbTx). Brevetoxins (PbTxs) are polycyclic polyether ladders with 
11 fused rings and have a molecular weight around 900 Da. Brevetoxin-3 and PbTx-2 are 
the most abundant of the brevetoxins with allylic alcohol and α, β- unsaturated aldehyde 
at K-ring side chains, respectively as shown in Figure 12. 
PbTx-3     PbTx-2 
Figure 12. Structure of PbTx-3 and PbTx-2 
 
 PbTxs are neurotoxins that bind to site 5 of the voltage-gated sodium channel of 
excitable membranes resulting in sodium influx into the cell and membrane 
depolarization, thus affecting the central nervous system as well as skeletal muscle59.  
The influx of sodium is believed to be the mechanism of the neurotoxic effects. However, 
several studies have reported increases in indicators of oxidative stress in manatee60 and 
loggerhead turtles61 that have been exposed to brevetoxins. The increase in oxidative 
stress is the indicative of an alternate mechanism of toxicity, which may broaden the 
range of effects of PbTx. In K. brevis cells, PbTx is localized in the chloroplast and is 
associated with a protein, thioredoxin62. Studies with mammalian thioredoxin reductase 
  24 
(TrxR1) show that PbTx-2 inhibits the reduction of Trx with an IC50 of 25 µM63, as 
shown in Figure 13A. However, it activates the DTNB reduction (Figure 13B) in an 
unprecedented way.  
 
  
 
Figure 13. (A) TrxR1/Trx inhibition by PbTx-2 (20 μΜ, ▲); control (only DMSO, ○). (B) DTNB 
reduction by rat recombinant TrxR1(0.56 μM) in the presence of PbTx-2 (18 μΜ, ▲); control 
(only DMSO, ○). Adapted from reference 63 
 
2.2 Rationale  
 
 The structure of many known inhibitors of TrxR have an α, β- unsaturated 
ketone/aldehyde functional group such as curcumin56, juglone, PbTx-263, mitomycin C64 
and many more. In many cases, the inhibitors, such as curcumin and possibly PbTx-2, 
acts as a Michael acceptor to the selenol of Sec. However, PbTx-2 activates reduction of 
DTNB by TrxR1 and inhibit insulin reduction, which has not been previously observed. 
The dual effect was attributed to the combination of the α, β- unsaturated aldehyde 
functional group and the large size of the brevetoxin molecule which might act as a 
wedge preventing the modified C-terminal tail from entering the tetrapeptide pocket and 
preventing reduction of the C-terminal redox center while at the same time, exposing the 
N-terminal redox center. We reasoned that other molecules with similar properties might 
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behave in the same fashion. Several compounds were identified that fit the desired 
criteria: an α, β- unsaturated carbonyl functional group and Mr over 500 amu. These 
compounds belong to broad categories that include toxins such as brevetoxin-3 (PbTx-3), 
microcystin LR (MC-LR) and nodularin (Figure 14) as well as antibiotics such as 
geldanamycin (Ga), rifamycin SV (Rf) and thiostrepton (Th), as shown in Figure 15. 
These compounds have alternative targets in vivo; however, TrxR may also be a common 
target for all these test compounds.  
                    
Microcystin-LR (MC-LR)      Reduced Microcystin-LR    
     (R = Adda group same as MC-LR) 
 
 
 
                 Nodularin 
Figure 14. Test compounds (toxins) to be screened with TrxR. The bonds in red are α, β-
unsaturated carbonyl moiety and shows the possible site of forming Michael adduct with Sec of 
TrxR 
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                   Geldanamycin                                                                      Rifamycin SV                                                                 
                 
              Manumycin A                              Dihydro-manumycin A     Deoxy-manumycin A  
       R1  and   R2 are same as manumycin A  
 
            Thiostrepton    
     
Figure 15. Test compounds (antibiotics) to be screened with TrxR. The bonds in red are α,β-
unsaturated carbonyl moiety and shows the possible site of forming Michael adduct with Sec of 
TrxR 
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2.3 Research objectives 
 
1. The first objective of this research is to determine if molecules which are similar in 
size and functionality to PbTx-2 will have the same dual effect on TrxR as does PbTx-
2. These compounds will be screened for the effect on DTNB, insulin and 
selenocystine reduction by cytosolic TrxR1, mitochondrial (mTrxR2) and (Drosophila 
melanogaster) DmTrxR. All three enzymes have similar mechanism of action to 
reduce their substrates but varies in homology.  
2. The second objective of this work shall focus on understanding the mechanism of 
inhibition/activation induced by these test compounds by employing site specific 
mutants of mTrxR2 and DmTrxR.  
3. The third objective is to evaluate the necessity of the functional group α, β-unsaturated 
carbonyl for inhibition of TrxR by considering specifically the above mentioned test 
compounds that have this functional group.  
4. Inhibition of TrxR is known to produce NADPH oxidase activity and increase the 
ROS. The current research will also study if TrxR inhibition by these test compounds 
is the source of ROS in vitro as well as in vivo using cellular model such as human 
lymphoblast cell particularly with PbTx-2.   
2.4 DTNB reduction by TrxR1 in the presence of α, β-unsaturated carbonyl 
compounds 
 
 Ellman’s reagent (5,5’-dithiobis-(2-nitrobenzoic acid)) or DTNB, contains a 
disulfide bond that is susceptible to attack by a nucleophile such as thiol or selenol with 
the release of yellow colored 2-nitro-5-thiobenzoate (TNB2-)65. The reaction occurs in a 
stoichiometric ratio, as shown in Figure 16. 
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                             Figure 16. Stoichiometric reaction of DTNB and nucleophile 
 
 Small molecule substrates, such as DTNB66 and juglone67, are known to be 
reduced by both N-as well as C-terminal redox active site. The reduction of DTNB by 
TrxR1 in the presence of the above mentioned test compounds resulted in activation at 
various degree except for Man-A, as shown in Figure 17. Such activation might be the 
result of a conformational change that results from the interaction with the C-terminal 
Sec by an electrophile25. Table 5 represents the relative rate of activation experienced by 
individual test compounds as compared to the control. The enzyme activity of the control 
is 634 ± 47.2 NADPH mol/min-mol enzyme.  
     
Figure 17. Reduction of DTNB (2 mM) by TrxR1 (5.12 nM) in the presence of test compounds 
(20 μΜ). PbTx-3 (△); MC-LR (◇); Th (□); Ga (×); PbTx-2(▲); Rf (●); Nodularin (◆); Man-A 
(■) and Control (○) 
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Table 5. Relative rate of test compounds (20 μΜ) as compared to wild type TrxR1(5.12 nM) in 
DTNB reduction (2 mM) 
   
Compounds  Relative rate   
PbTx-3 6.04** 
PbTx-2 2.60** 
MC-LR 3.32** 
Dihydro MC-LR 3.55** 
Nodularin 1.47** 
Ga  2.67** 
Rf 2.33** 
Th  2.35** 
Man-A 0.05** 
Dihydroman-A 0.91 
Deoxyman-A 0.10** 
 
2.5 Enzymes to be used in this study 
 
 The enzymes used in this research are listed in Table 6. Two isoforms of human 
TrxR: cytoplasmic and mitochondrial, and a TrxR that belong to a different class, insecta 
(DmTrxR) were used. Although they are all homodimers with similar mechanism of 
action, each enzyme has different roles and different substrate specificity. All of these 
enzymes utilize a C-terminal Sec for reducing substrates. The C-terminal Sec site is also 
susceptible to inhibition by many electrophiles. Substitution of the C-terminal Sec by less 
nucleophilic Cys or rendering the C-terminal unfunctional can reveal the in-depth 
mechanism of interaction of the test compounds with TrxR. The dead tail mutant of 
mTrxR and DmTrxR rely solely on their N-terminal redox centers to reduce their 
substrates and could reveal valuable information of where the test compounds are 
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interacting. In addition to the truncated version, the dead tail mutant does not have the 
active C-terminal redox center. In the absence of the C-terminal tail, the test compounds 
could react with exposed N-terminal thiol and shut down the truncated enzyme 
completely. On the other hand, the dead tail enzyme which has a non-functional tail may 
prevent the test compound from interacting with the N-terminal redox center. By the use 
of different class and mutants the complete picture of mechanism of action between test 
compounds and TrxR could be elucidated. Furthermore, these enzymes will illustrate the 
role and necessity of C-terminal Sec in TrxR and α, β-unsaturated functional moiety in 
test compounds for the activation that is observed in DTNB reduction.  
Table 6. List of enzymes screened for DTNB reduction with α, β-unsaturated carbonyl 
compounds 
 
Enzymes C-terminal redox center 
TrxR1 (GCUG) GCUG 
mTrxR2 (GCUG) GCUG 
mTrxR2 (GCCG) GCCG 
mTrxR2 (GSSG) Dead tail mutant (GSSG) 
mTrxR2 (Δ8) 8 amino acid truncated enzyme at C-terminal 
DmTrxR (SCCS) SCCS 
DmTrxR (SCUG) SCUG 
DmTrxR (Δ8) 8 amino acid truncated enzyme at C-terminal 
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2.6 Conclusion 
 
 All of the test compounds activate the DTNB reduction of TrxR1, except for Man-
A. Man-A shows a characteristic behavior of typical inhibitor by preventing reduction of 
DTNB, which suggest a possible reaction at C-terminal redox center. As the redox center 
is modulated by the test compounds that activate DTNB reduction, it could be concluded 
that these test compounds interact with the C-terminal tail in some novel manner not 
observed until now. This will be the subject of studies reported herein. 
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Chapter 3. Manumycin-A, a potent inhibitor of mammalian thioredoxin reductase-1 
and activator of thioredoxin reductase-2 
 
3.1 Objective 
 
 A literature search of compounds which are similar in size and functionality to 
brevetoxin, included the farnesyl transferase inhibitor manumycin-A (Man-A). Man-A 
has numerous electrophilic sites that might contribute to the formation of a Michael 
adduct with the Sec residue of TrxR or alkylation via the epoxide. Initial screening in a 
DTNB reduction assay indicated that Man-A is indeed a TrxR inhibitor. The objective of 
the work presented in this chapter is to understand the mechanism of inhibition of TrxR1 
by Man-A. This shall be accomplished by using enzyme assays that are dependent upon 
TrxR and Trx and a selenol specific probe. Both cytosolic TrxR1 and mitochondrial 
TrxR2 (mTrxR) as well as TrxR2 mutants that have point mutations in the C-terminal 
redox center shall be evaluated. The reactive site at Man-A will also be determined using 
derivatives of Man-A, dihdyro-manumycin A and deoxy-manumycin A.  
 3.2. Introduction 
 Man-A (Figure 18) is a bacterial secondary metabolite that was first isolated from 
Streptomyces parvulus as a result of a random screening program for farnesyl transferase 
(FTase) inhibitors68. FTase catalyzes the post-translational farnesylation of proteins 
including the Ras family of proteins. FTase links the farnesyl isoprenyl moiety to the 
carboxy terminal of Ras. The farnesylation of Ras allows its mobilization to lipid rich cell 
membrane by increasing the hydrophobicity. Ras is a guanosine nucleotide binding 
protein. When localized to the cell membrane, the Ras bound GDP (Guanosine 
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diphosphate) is phosphorylated to GTP (Guanosine triphosphate), activating Ras and 
initiating the cascade of phosphorylation that triggers Ras-MAPK (mitogen-activated 
protein kinases) signaling. Ras proteins regulate numerous functions, which are related to 
cell growth, proliferation and cell signaling. They function by binding to and activating 
several effector proteins which regulate critical cellular processes including transcription, 
translation, cell-cycle progression and calcium signaling69. FTase inhibitors block 
farnesylation such that Ras remains in the cytosol and does not stimulate its downstream 
targets. Ras is the most frequently mutated oncogene in human cancers with as many as 
25% of known human tumors having mutated Ras70. FTase inhibitors have been 
discovered and developed for the treatment of cancers71-72 as well as progeria73 and 
parasitic infections74-77. Man-A inhibits rat brain FTase with a Ki of 1.2 µM68 and has 
shown antitumor activity in a variety of cancer cell types78-79 and tumor models80-81.  
     
Figure 18. Manumycin A 
 The tumoricidal activity of manumycin was initially attributed to the inhibition of 
FTase preventing activation of Ras. However, it soon became apparent that the 
cytotoxicity of Man-A included pathways which were independent of Ras. Numerous 
studies report the induction of reactive oxygen species (ROS) or more specifically, 
superoxide radical anion (O2-.) in Man-A treated cells and tumors82-91.  
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 The thioredoxin system is a major regulatory system for the maintenance of redox 
homeostasis of the cell. The reduced TrxR reduces Trx which then reduces other proteins. 
But the reduced TrxR is susceptible to attack by electrophiles. The electrophilic sites of 
Man-A, as shown in Figure 19, include the central epoxide and the cyclohexeneone, the 
cyclopenteneone and the two polyunsaturated carbonyls of the side chains. These 
functional groups could react with the nucleophilic Sec of TrxR.  
     
Figure 19. Electrophilic sites present in Man-A 
 
3.3. Results and Discussion  
 
3.3.1 DTNB as a substrate for TrxR1 and mTrxR WT and mutants 
 
 The cytosolic TrxR1 and mitochondrial TrxR2 enzymes studied in this chapter are 
presented in Table 7.  
Table 7. Enzymes used in screening Man-A 
 
Enzymes (C-terminal sequence) Type 
TrxR1 (GCUG) Cytosolic recombinant rat wild type 
mTrxR2 (GCUG) Wild type (WT) 
mTrxR2 (GCCG) Cysteine mutant 
mTrxR2 (GSSG) Serine mutant “dead tail” 
mTrxR2 (Δ8) Truncated mutant 
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 The DTNB reduction by TrxR1 after incubation with 5 μM Man-A for 60 min 
showed complete inhibition (Figure 20A) as a typical inhibitor such as auranofin or 
curcumin but unlike PbTx-2. The inhibition of TrxR1 by Man-A appeared to be time 
dependent. When reduced TrxR1 was pre-incubated with Man-A the initial rate (V0) of 
DTNB reduction was reduced to 25.4% of the control.  On the other hand, when Man-A 
was not pre-incubated with TrxR1, V0 was 49.1% of the control (Figure 20B). The initial 
rates are calculated based on the polynomial regression of the trend line.  
 Dose response curves for the inhibition of DTNB reduction by Man-A confirmed 
that TrxR1 inhibition by Man-A is indeed time dependent.  When pre-incubated for 60 
minutes the IC50 was 272 (±29) nM whereas the IC50 increased to 1586 (±128) nM 
without pre-incubation. At higher concentration (5 μM), both the pre-incubated and not 
pre-incubated samples have the same inhibition (Figure 21A). These data indicate that the 
inhibition of Man-A by TrxR1 is time dependent at lower concentrations. For the 
concentration of 1 μM, the reaction was completed within 10 minutes. (Figure 21B).
        
Figure 20. Reduction of DTNB by TrxR1 in the presence of Man-A (A) Inhibition of DTNB (2 
mM) reduction by TrxR1 (5.6 nM) after sixty minutes incubation with Man-A (5 μM, □); Control 
(DMSO only, ○). (B) Effect of pre-incubation of Man-A with reduced TrxR1 (5.6 nM) on DTNB 
reduction. Reduced TrxR1 pre-incubated (□) and not pre-incubated (▲) with Man-A (1800 nM) 
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Figure 21. (A) Inhibition of DTNB (2 mM) reduction by TrxR1 (5.6 nM) in the presence of Man-
A (0-5000 nM). Sixty minutes pre-incubation with Man-A (□). No pre-incubation (▲). Results 
are expressed as initial rates relative to control (no Man-A).  (B) Time course of inhibition of 
DTNB reduction by TrxR1 (5.6 nM) in the presence of Man-A (1μM). Control (DMSO only, ○) 
Incubation times 15 min (×); 10 min (◆); 5 min (▲); 2 min (■) after Man-A addition 
 
 Man-A appears to be a typical inhibitor of TrxR1, inhibiting DTNB reduction. On 
the other hand, the effect of Man-A on mTrxR2 was quite different. Man-A activates the 
DTNB reduction by mTrxR2 enzymes (Figure 22) to different degrees. In this way, Man-
A behaves towards mTrxR2 in the same way that PbTx-2 behaves towards TrxR1. The 
mTrxR2 (GCCG) mutant is capable of using the C-terminal redox center to reduce its 
substrates. Indeed, numerous isoforms of TrxR function effectively with a C-terminal 
GCCG. However, both the mTrxR2 (GSSG) and the mTrxR2 (Δ8) depend solely on the 
N-terminal redox center for DTNB reduction. It is noteworthy that the highest level of 
activation, 4.9-fold when compared to the mTrxR2 (GSSG) control, is observed in the 
dead tail mutant with. The truncated mutant in which the N-terminal redox center is 
already exposed showed the smaller activation of 2.5-fold compared to control. These 
data, taken together suggest that Man-A binds to mTrxR2 at or near the C-terminal tail, 
preventing the tail from tucking into the tetrapeptide pocket and exposing the N-terminal 
redox center. The truncated mutant already has the N-terminal redox center exposed and 
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therefore experiences the smallest activation among the mTrxR2 mutants. The WT and 
cysteine mutant of mTrxR experienced 1.5 and 4.5-fold activation respectively when 
compared to their controls, as shown in Table 8. 
  
          
Figure 22. Reduction of DTNB (2 mM) by mTrxR (5.12 nM) in the presence of Man-A. (Α) 
mTrxR2 (GCUG) (WT) (B) mTrxR2 (GCCG); C. mTrxR2 (GSSG) and D. mTrxR2 (Δ8). Control 
(DMSO only, ○); Man-A (6 μΜ, □) 
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Table 8. Relative rate of DTNB reduction by mTrxR2 in the presence of Man-A (6 μM) as 
compared to their respective control. The consumption of DTNB was calculated from standard 
curve of TNB2- 
 
mTrxR2 enzyme Relative rate 
mTrxR2 (CGUG) 1.56** 
mTrxR2 (GCCG) 4.54** 
mTrxR2 (GSSG) 4.85** 
mTrxR2 (∆8) 2.45** 
The number of asterisks indicate significant differences compared with control (** p <0.01) 
 
3.3.2 Irreversible inhibition of TrxR1 by Man-A 
 
 In an effort to determine if the inhibition of TrxR1 by Man-A is reversible, the 
DTNB reduction assay was performed as before however, after 1 hour incubation of pre-
reduced TrxR1 with 2.45 M Man-A, the mixture was passed through a gel filtration 
column (MW cutoff of 6000 amu) followed by a 30 min incubation with additional 
NADPH. Gel filtration should remove all unbound Man-A from the solution and the 
subsequent 30 min incubation should allow for reestablishing equilibrium. As shown in 
Figure 23, this treatment still resulted in complete inhibition of TrxR1 demonstrating that 
the inhibition of TrxR1 by Man-A is irreversible. It is particularly important to note that 
Man-A has no effect on the rate of DTNB reduction when incubated with TrxR1 which 
has not been reduced with NADPH. When oxidized TrxR1 is incubated with Man-A for 
30 min, followed by gel filtration to remove Man-A, TrxR1 activity is restored 
completely upon reduction with NADPH. This observation demonstrates that either the 
N-terminal or C-terminal redox centers, or both must be reduced for Man-A to have an 
effect on TrxR1. Furthermore, it suggests that one or both are sites of reactivity with 
Man-A.  
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Figure 23. Test of irreversibility of inhibition of DTNB reduction by TrxR1 (5.2 nM) in the 
presence of Man-A (2 μM). TrxR1 reduced only after removal of Man-A by gel filtration (◆); 
Control (no Man-A, ○); Man-A not subjected to gel filtration (▲); Man-A removed by gel 
filtration after incubation with reduced TrxR1 (□) 
 
 On the other hand, when the mTrxR enzymes were treated with Man-A in an 
identical manner, the enzymes were no longer activated after passing through a size 
exclusion gel. This suggests that the Man-A can be removed and that the interaction 
between Man-A and the mTrxR enzymes is non-covalent or is at least reversible as 
shown in Figure 24. 
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Figure 24. Test of irreversibility of inhibition of DTNB (2 mM) reduction by (A) mTrxR2 
(CGUG) (B) mTrxR2 (GCCG) (C) mTrxR2 (GSSG) (5.2 nM) in the presence of Man-A (4.2 
μM). mTrxR reduced only after removal of Man-A by gel filtration (◆); Control (no Man-A, ○); 
Man-A removed by gel filtration after incubation with reduced TrxR1 (□) 
 
3.3.3 TrxR/Trx insulin reduction in the presence of Man-A 
 
 The effect of Man-A on the thioredoxin system was examined using an assay 
which is based on the reduction of eosin modified insulin by Trx92. In this two-enzyme 
assay, oxidized Trx is continuously reduced by TrxR1 with reducing equivalents 
ultimately provided by NADPH. The fluorescent signal is only possible when insulin is 
reduced by Trx. This means the electron flow should follow the sequence a shown in 
Figure 25. When the electron flow is disrupted by inhibition of TrxR1, the insulin 
reduction is prevented and as a result no fluorescence is observed. The dose response 
curve for Man-A and TrxR1 shown in Figure 26 indicates that Man-A inhibits insulin 
reduction by TrxR1 with an IC50 of 572 ( 88) nM. 
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Figure 25. TrxR/Trx insulin reduction 
 
 
 
Figure 26. Dose-response curve with increasing concentration of Man-A (0-1000 nM) TrxR1/Trx 
insulin reduction assay. Results expressed as percent inhibition by Man-A vs. concentration 
 
 Man-A inhibits both insulin reduction and DTNB reduction by TrxR1 but 
activates DTNB reduction and inhibits insulin reduction by mTrxR2 enzymes in a similar 
manner to PbTx-2 with TrxR163 (Figure 27). This inhibition observed in insulin reduction 
suggests Man-A interferes at the C-terminal tail so as to prevent the electron flow towards 
thioredoxin. Both insulin reduction and gel filtration experiment suggest that Man-A 
forms a covalent adduct with TrxR1 and either a reversible covalent or a non-covalent 
adduct with mTrxR2 (GCUG). 
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Figure 27. Inhibition of insulin reduction by mTrxR2 (CGUG) (200 nM) in the presence of Man-
A (10 μM, □); Control (no Man-A, ○) 
 
3.3.4. Reactivity of Man-A with seleno-L-cysteine and reduced TrxR1 
 
 Numerous electrophiles inhibit mammalian TrxR by alkylating the C-terminal 
Sec. These electrophiles are mainly α, β-unsaturated carbonyl compounds that 
irreversibly react with TrxR. Inspection of the Man-A structure reveals numerous 
potential sites of reactivity. In addition to the epoxide, any of the four mono- or poly 
unsaturated carbonyl groups of Man-A may alkylate the Sec of TrxR. The selenol 
selective probe Sel-green was used to evaluate the reactivity of Man-A with Sec. The 
strongly nucleophilic, reduced selenol undergoes nucleophilic aromatic substitution with 
the probe, which then releases the fluorophore as shown in Figure 28. When Sec is 
alkylated it will not react with the probe and fluorescence will be suppressed. Figure 29A 
demonstrates that the release of fluorescent reporter by Sec is inhibited in the presence of 
Man-A indicating that Man-A reacts with Sec. A similar experiment with TrxR1 was 
performed to evaluate the reactivity of Man-A as presented in the Figure 29B. Man-A 
treated TrxR1 resulted in 15 % inhibition.  
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Figure 28. Reaction of Sel-green probe. Adapted from reference 93 
 
          
Figure 29. (A) Reaction of reduced selno-L-cysteine (20 μM) with Sel-green probe (20 μM) in 
the presence of Man-A (20 μM). (B) Reaction of TrxR1 (4.2 μM) with Sel-green probe (48 μM) 
in the presence of Man-A (20 μM). Data represented at 60 min 
 
3.3.5. Determining the reactive site of Man-A 
 
 Many electrophilic sites in Man-A are susceptible to nucleophilic attack by Sec. 
Identification of electrophilic site responsible for TrxR1 inhibition was evaluated with 
two derivatives of Man-A; deoxy-manumycin A, which lacks both the epoxide and the 
cyclohexenone and dihydro-manumycin A which lacks the cyclohexenone (Figure 30). 
The selenol selective probe Sel-green93 was used to evaluate the reactivity of Man-A 
derivatives with Sec. Under the same conditions used for Man-A, deoxy-Man A reduced 
the fluorescence by 24.6% compared to control and dihydro-Man A showed no reduction 
of fluorescence, indicating that Man-A reacts readily with Sec while its derivatives do not 
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as shown in Figure 31. This suggests the possible reactive site at Man-A is the 
cyclohexanone moiety.  
 
                 
Figure 30. Structure of Man-A derivatives. (A) Deoxy-manumycin-A. (B) Dihydro-manumycin-
A. R1 and R2 are identical to Man-A 
 
Figure 31. Reaction of reduced seleno-L-cysteine (20 μM) with Sel-green probe (20 μM) in the 
presence of Man-A and derivatives (20 μM). Data represented at 60 min 
 
 
3.3.6. TrxR1/Trx insulin reduction in the presence of Man-A derivatives 
 
 Neither deoxy-Man-A nor dihydro-Man-A inhibits insulin reduction by the 
TrxR1/Trx system at concentrations of 20 M as shown in Figure 32. This result is 
consistent with the reactivity of Man-A and its derivatives with Sec. While Man-A has 
several electrophilic sites, the site of reactivity with TrxR1 must be the α, β-unsaturated 
ketone. Even though deoxy-manumycin A showed some reactivity with Sec, it did not 
inhibit insulin reduction. This could possibly be due to steric hindrance due to large size 
of TrxR1 as compared to Sec.  
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Figure 32. Insulin reduction by TrxR1/Trx in the presence of 20 M each of deoxy-man-A (▲); 
dihydro-man-A (◆); Man-A (□); Control (DMSO only, ○) 
 
3.3.7. NADPH oxidase activity of TrxR in the presence of Man-A  
 
 The chemical modification of the C-terminal Sec of TrxR1 yields a SecTRAP 
(selenium compromised thioredoxin reductase-derived apoptotic proteins)52, promoting 
both apoptosis and necrosis via oxidative stress and increased intracellular reactive 
oxygen species (ROS) production. Both curcumin and juglone modified TrxR1 have 
demonstrated strongly induced NADPH oxidase activity, producing O2-• in the presence 
of oxygen via the N-terminal (Cys59/Cys64) redox center67, 94-95. In addition to increased 
ROS, Man-A treated cells have shown NADPH oxidase activity88, decreased TrxR1 
activity85 and decreased Trx expression87. One reason for activation of NADPH oxidase 
activity may be due to the alkylation of TrxR1, producing a SecTRAP. Transfection of 
cells with SOD and TrxR cDNA or pre-treatment with ROS scavengers has been shown 
to block the adverse effects of Man-A96. The NADPH consumption by TrxR1 in the 
absence of a disulfide substrate was examined (Figure 33A). When pre-incubated with 
62.5 μM Man-A, the consumption of NADPH by TrxR1 is increased 5-fold relative to the 
control.  
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 Superoxide can reduce cytochrome c, and in the presence of Man-A treated 
TrxR1, it was monitored over time with and without the addition of SOD (Figure 33B). If 
superoxide is produced by Man-A treated TrxR1, then the addition of SOD should inhibit 
cytochrome c reduction. This was indeed the case. The rate of cytochrome c reduction 
was decreased to control level in the presence of SOD when compared to the Man-A 
treated sample alone.   
       
Figure 33. (A) NADPH consumption by TrxR1 (0.2 μM) induced by Man-A (62.5 μM). (B) 
Reduction of cytochrome c (100 μM) by O2-• generated by TrxR1 (100 nM) in the presence of 
Man-A (62.5 μM); Man-A and SOD (62.5 μM and 6 unit/well); control (DMSO only). The 
number of asterisks indicate significant differences compared with control (p <0.05) 
 
 As shown in Figure 34, Man-A also induces NADPH oxidation in mTrxR and 
mTrxR mutants to varying degrees. When compared to control, Man-A increased 
NADPH consumption by mTrxR2 (GCUG) by 4.4-fold, the cysteine mutant by 3.4-fold, 
the dead tail mutant by 14-fold and the truncated mTrxR2 by 4.4-fold (SeeTable 9). 
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Figure 34. NADPH oxidase activity of mTrxR (0.2 μΜ) induced by Man-A (38.5 μΜ). (A) 
mTrxR2 (GCUG); (B) mTrxR2 (GCCG); (C) mTrxR2 (GSSG); (D) mTrxR2 (Δ8). The data is 
represented as NADPH consumption by mTrxR variants in the presence of Man-A. The number 
of asterisks indicate significant differences compared with control (* p <0.05, ** p <0.01) 
 
Table 9. NADPH consumption by TrxR in the presence of Man-A. NADPH consumed expressed 
as NADPH mol/min-mol enzyme 
 
  
TrxR1 
mTrxR2 
(GCUG) 
mTrxR2 
(GCCG) 
mTrxR2 
(GSSG) 
mTrxR2 
 (∆8) 
Control 3.25 ± 2.99 0.93 ± 0.14 0.40 ± 0.15 0.11 ± 0.04 0.49 ± 0.43 
Man-A 17.6 ± 1.98* 3.76 ± 1.48** 1.38 ± 0.17**  1.53 ±0.10** 1.9 ± 1.10** 
The number of asterisks indicate significant differences compared with control (* p <0.05, ** p 
<0.01) 
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3.3.8 Reactivity of TrxR1 and mTrxR variants with substrate selenocystine in the 
presence of Man-A 
 
 Reduction of selenocystine is believed to require a functional C-terminal redox 
center with either Cys or Sec, but both are not required. However, the rate is much faster 
when Sec is present25. The diselenide bond undergoes nucleophilic attack by the C-
terminal reduced Cys/Sec forming the new diselenide or selenosulfide bond with the 
substrate selenocystine. This diselenide or selenosulfide bond is then reduced by an N-
terminal thiol as shown in Figure 35. This mechanism further illustrates the inability of 
the dead tail (GSSG) and truncated (Δ8) mutants to reduce selenocystine. The rate of 
selenocystine reduction is measured by monitoring the consumption of NADPH. 
Comparison of Figure 36A and Figure 36B indicates that in the presence of Sec, NADPH 
consumption is significantly faster and can be attributed to the presence of selenocystine 
as a substrate. Given that Man-A react with TrxR1 in a time dependent manner, in the 
absence of pre-incubation, Man-A induced 1.3-fold enhancement with TrxR1 and 2.5-
fold ehhancement as compared to mTrxR2 (CGUG) control. This also points out to the 
fact that initially Man-A reacts with Cys in a reversible manner and later forms a covalent 
adduct with Sec of TrxR1.The rate of NADPH consumption for the mTrxR2 (GCCG) 
mutant is very slow when compared to the mTrxR2 (CGUG) (Figure 36C and Table 10). 
This demonstrates the importance of Sec in selenocystine reduction. In the presence of 
Man-A (38.5 μM), the rate of selenocystine reduction for mTrxR2 (GCCG) is comparable 
to that of the control.  
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Figure 35. Mechanism of reduction of selenocystine by mammalian TrxR. Adapted from 
reference 25 
 
   
    
Figure 36. Selenocystine reduction by TrxR (20 nM) in the presence of Man-A (38.5 μM) 
without incubation. (A) TrxR1; (B) mTrxR2 (CGUG); (C) mTrxR2 (GCCG). The data is 
expressed as NADPH consumption. The number of asterisks indicate significant differences 
compared with control (* p <0.05, ** p <0.01) 
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Table 10. Rate of selenocystine reduction by TrxR in the presence of Man-A without incubation. 
Data expressed as NADPH mol/min-mol enzyme 
 
 TrxR1 
mTrxR2 
(GCUG) 
mTrxR 
(GCCG) 
Control 1065 ± 150 794 ± 35.1 388 ± 142 
Man-A 1375 ± 84.0** 1972 ± 278** 338 ± 147 
The number of asterisks indicate significant differences compared with control (* p <0.05, ** p 
<0.01) 
However, after 15 minutes incubation of Man-A with reduced TrxR prior to 
addition of selenocystine resulted in complete inhibition as comparable to auranofin with 
TrxR1. Considering the fact the reaction of Man-A with TrxR1 is time dependent (at least 
10 minutes), as shown in Figure 21B, 15 minutes incubation of Man-1 with TrxR1 
ensures an equilibrium time required for alkylation at Sec thus inhibiting selenocystine 
reduction (Figure 37A and Table 11). The cysteine mutant, mTrxR2 (GCCG) when  
incubated with Man-A inhibited the reduction of selenocystine reduction, as shown in 
Figure 37B and Table 11. However, Man-A reacts with mTrx2 (GCUG) by activating the 
reduction of selenocystine by 1.6-fold suggesting the C-terminal Sec is free. 
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Figure 37. Selenocystine reduction by TrxR (20 nM) after 15 minutes incubation with Man-A 
(38.5 μM). The substrate was added after incubation of 15 minutes. (A) TrxR1; (B) mTrxR2 
(CGUG); (C) mTrxR2 (GCCG). The data is expressed as NADPH consumption during reduction 
of selenocystine. The number of asterisks indicate significant differences compared with control 
(* p <0.05, ** p <0.01) 
 
Table 11. Rate of selnocystine reduction by TrxR after 15 minutes ncubation with Man-A. Data 
expressed as NADPH mol/min-mol enzyme  
 
 TrxR1 
mTrxR2 
(GCUG) 
mTrxR 
(GCCG) 
Control  337 ± 80.5 347 ± 21.5 82.2 ± 18.8 
Man-A 13.3 ± 62.4** 552 ± 107* -13.2 ± 32.5* 
Auranofin 15.2 ± 19.0** 1.67 ± 6.14** 8.00 ±8.35** 
The number of asterisks indicate significant differences compared with control (* p <0.05, ** p 
<0.01) 
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3.3.9 Reactivity of TrxR1 and mTrxR2 (GCUG) with substrate hydrogen peroxide in 
the presence of Man-A 
 
 Reduction of hydrogen peroxide  requires C-terminal Sec as the Cys mutant97-98  
is unable to do so. The nucleophilic Sec is oxidized to selenic acid (-SeOH) by H2O2 
which in turn is reduced by adjacent Cys497. In the presence of Man-A, as shown in 
Figure 38 and Table 11, the reduction of H2O2 is inhibited 12-fold by TrxR1 and 1.5-fold 
by mTrxR2 (GCUG) as compared to its respective controls. The inhibition also 
emphasizes the interaction of Man-A initailly with Cys497 which would prevent reduction 
of oxidized Sec. 
       
Figure 38. Hydrogen peroxide reduction by TrxR (50 nM) in the presence of Man-A (38.5 μM) 
and auranofin (38.5 μM).  (A) TrxR1; (B) mTrxR2 (CGUG). The data is expressed as NADPH 
consumption during reduction of H2O2 (50 mM). The number of asterisks indicate significant 
differences compared with control (* p <0.05, ** p <0.01) 
 
 Table 12. Rate of H2O2 reduction by TrxR in the presence of Man-A and auranofin. Data 
expressed as NADPH mol/min-mol enzyme 
                     
 TrxR1 mTrxR2 (GCUG) 
Control  268±18.5 341 ±8.20 
Man-A 23.0±4.62** 225 ± 17.6** 
Auranofin 16.6±13.6** 16.6 ±5.71** 
The number of asterisks indicate significant differences compared with control (* p <0.05, ** p 
<0.01) 
 
0
100
200
300
400
Control Man-A Auranofin
N
A
D
P
H
 m
o
l/
m
in
-m
o
l 
e
n
z
y
m
e
****
A
0
100
200
300
400
Control Man-A Auranofin
N
A
D
P
H
 m
o
l/
m
in
-m
o
l 
e
n
z
y
m
e
**
**
B
  53 
 When incubated for 15 minutes with reduced TrxR, Man-A completely inhibited 
reduction of H2O2 (14-fold) as comparable to auranofin. While pre-incubation results in 
only partial inhibition (1.3-fold) with mTrxR2 (GCUG), as shown in Figure 39 and Table 
13. These results also corroborate that Man-A initially interacts with Cys497 of TrxR1. 
The inhibition of H2O2 reduction by mTrxR2 (GCUG) in the presence of Man-A (1.3-
fold) could be due to the non-covalent interaction with mTrxR2 (GCUG). 
  
Figure 39. Hydrogen peroxide reduction by TrxR (50 nM) after 15 minutes incubation with Man-
A (38.5 μM) and auranofin (38.5 μM).  (A) TrxR1; (B) mTrxR2 (CGUG). The data is expressed 
as NADPH mol/min-mol enzyme during reduction of H2O2 (50 mM). The number of asterisks 
indicate significant differences compared with control (* p <0.05, ** p <0.01) 
 
Table 13. Rate of H2O2 reduction by TrxR after 15 minutes incubation with Man-A and 
auranofin. Data expressed as NADPH mol/min-mol enzyme 
 
 TrxR1 mTrxR2 (GCUG) 
Control  185 ±21.0 235 ± 22.6 
Man-A 13.3 ± 14.1** 177 ± 15.4* 
Auranofin 11.1 ±10.0** 27.9 ± 29.9** 
The number of asterisks indicate significant differences compared with control (* p <0.05, ** p 
<0.01) 
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3.3.10 Reactivity of Man-A in cell homogenate 
 
 Man-A has many electrophilic sites that can be the targets of numerous 
nucleophiles in vivo and prevent it from reacting with TrxR.  In order to determine if 
Man-A could inhibit TrxR under physiological conditions, TrxR1 activity of human 
lymphoblast (GM02152) cell lysate in the presence of Man-A (1 μM) was analyzed using 
the insulin reduction assay. The ratio of initial rates of insulin reduction for control:Man-
A treated sample is 2.3:1.  There appears to be a longer induction time in the Man-A 
treated sample as shown in Figure 40A. However, the manufacturer of the assay kit 
recommends comparing rates between 15 and 45 minutes. Here the relative rates for 
control: Man-A treated sample is 1.2:1. This induction time may be due to the presence of 
numerous endogenous nucleophiles which may be susceptible to react with Man-A. 
Comparing the percent of TrxR1 inhibition at sixty minutes, the Man-A treated cell 
homogenate show only 26 % inhibition as compared to control (DMSO) treated cells as 
shown in Figure 40B.  
  
Figure 40. (A)TrxR1/Trx insulin reduction assay with cell homogenate (GM02152, 15.6 μg of 
protein) in the presence of Man-A (1 μM). (B) Data in A represented as bar graph. Man-A (□); 
Control (DMSO only, ○) 
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3.4 Conclusion 
 
  The summary of all the enzymatic assays in the presence of Man-A are given in 
Table 14. Man-A acts as a typical irreversible inhibitor of human TrxR1, inhibiting both 
DTNB and Trx reduction. The low IC50 of 272 nM for DTNB reduction in the presence 
of Man-A suggest that it is a potent inhibitor of TrxR1.  
Table 14. Summary of TrxR activity in the presence of Man-A 
 
Enzymes TrxR1 
mTrxR2 
(GCUG) 
mTrxR2 
(GCCG) 
mTrxR2 
(GSSG) 
mTrxR2 
(Δ8) 
DΤΝΒ reduction Inhibit Activate Activate Activate Activate 
Insulin reduction Inhibit Inhibit - - - 
DTNB reduction after size 
exclusion 
Inhibit 
No 
activation 
No 
activation 
No 
activation 
- 
NADPH oxidase Activate Activate Activate Activate Activate 
Selenocystine reduction Activate Activate Activate - - 
Selenocystine reduction (15 
minutes incubation) 
Inhibit Activate Inhibit - - 
H2O2 reduction Inhibit Inhibit - - - 
H2O2 reduction (15 minutes 
incubation) 
Inhibit Inhibit - - - 
 
 On the other hand, Man-A behaves in an unprecedented way, similar to PbTx-2 
with WT and mutants of mTrxR2 by activating DTNB and inhibiting insulin reduction. 
Insulin reduction requires a functional C-terminal tail and the substitution of C-terminal 
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redox center Cys/Sec with Ser, truncation or alkylation should result in inhibition in 
insulin reduction as shown in Figure 41.   
 
Figure 41. TrxR/Trx inhibition mechanism and in the presence of Man-A 
 
 Man-A forms an irreversible adduct with TrxR1 as Man-A incubated TrxR1 
completely inhibited DTNB reduction even after passage through a size exclusion gel. In 
contrast to TrxR1, Man-A failed to activate DTNB reduction after passage through a size 
exclusion gel filter with mTrxR mutants. One possible explanation for this result would 
be that Man-A forms a reversible adduct with mTrxR or non-covalently interacts with the 
C-terminal tail of mTrxR.  
 Surprisingly, the reduction of selenocystine by TrxR1 was not inhibited by Man-A 
rather enhanced in absence of pre-incubation. This observation suggests that in the 
presence of Man-A, TrxR1 retains an unmodified Sec residue. This is contradictory to the 
earlier conclusion that Man-A reacts with Sec of TrxR1. It is generally believed that 
efficient selenocystine reduction requires a Sec residue in the C-terminal redox center, as 
the rate of selenocystine reduction by the mTrxR2 (GCCG) mutant is only about 1/3 that 
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or the WT enzyme25. However, the proposed mechanism of selenocystine reduction does 
not involve the C-terminal Cys residue. This raises the possibility that it is the Cys 
residue to be modified in TrxR1 under the given condition. Given the relative 
nucleophilicities of thiols vs selenols, this conclusion seems counterintuitive. The crystal 
structure of human TrxR1 (GCCG) revealed three possible conformations. In solution the 
more favorable conformation of reduced TrxR1 has the Cys497 more accessible than the 
Sec498 residue26.  Reaction of Man-A with Cys497 could leave the Sec498 residue free to 
reduce selenocystine, as shown in Figure 42.However, when pre-incuabated with reduced 
TrxR, Man-A induced inhibition of both selnocystine and H2O2 reduction by TrxR1 
revealing the reaction of Sec is not instant and is time dependent, as shown in Figure 42. 
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Figure 42 . The hypothesized mechanism of reduction of selenocystine in the presence of Man-A 
(A) non-covalent interaction between Man-A and Cys497 of TrxR (B) Nucleophilic attack of Sec498 
on diselenide bond of selenocystine (R-Se-Se-R) (C) The new diselenide bond formed between 
Sec498 and Sec of selenocystine resolved by N-terminal redox center (D) Covalent interaction 
between Man-A and Sec498 of TrxR 
  
  The DTNB reduction by TrxR1 in the presence of Man-A derivatives, suggests 
the central cyclohexenone is the reactive site in man-A. This functional group is absent in 
deoxy-man-A and dihydro-man-A. This conclusion is supported by the failure of these 
derivatives to inhibit insulin reduction by TrxR1 and decreased reactivity with seleno-L-
cysteine by deoxy-man-A and no reactivity with dihydro-man-A. If Man-A reacted at the 
C-terminal Sec, it could form Michael adduct as shown in Figure 43.  
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Figure 43. Proposed mechanism of reactivity of Man-A with TrxR1 after pre-incubation 
 
 Inhibition of TrxR at the C-terminal tail produces a SecTRAP and activates 
NADPH oxidase in cells. Reaction of Man-A with Cys497 may prevent the C-terminal tail 
to efficiently swing back into tetrapeptide binding pocket and hence interrupts the 
electron flow. In the presence of Man-A, NADPH oxidase activity was increased in both 
TrxR1 and mTrxR enzymes with a maximum of 14-fold in the dead tail mutant.  These 
results could explain apoptosis induced by the production of O2-. anion that was 
previously unknown. 
 The Man-A treated cell homogenate showed a longer induction time as compared 
to control in the insulin reduction assay. The presence of numerous nucleophiles which 
could be possible targets of Man-A in addition to TrxR in living cell. This research 
reveals the TrxR system is a cellular target of Man-A. Not only does Man-A inhibit Ras 
and downstream processes, it also interferes with redox homeostasis and stimulates ROS 
production as shown in Figure 44. 
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Figure 44. The cellular effects of Man-A as an inhibitor of FTase and TrxR1. FTase causes 
posttranslational modification of Ras which initiates a cascade of phosphorylation that triggers 
Ras-MAPK (mitogen-activated protein kinases) signaling. Inhibition of TrxR1 by Man-A 
activates NADPH oxidase, increasing the production of ROS. Inhibition of TrxR also prevents the 
reduction of Trx. Reduced Trx binds the ASK1 protein which is released when Trx is oxidized. 
Release of ASK1 activates many proteins such as AP-1 which are related to apoptosis. 
Posttranslation modification of Ras adapted from 99 
3.5 General materials and methods 
 
 Manumycin A, deoxymanumycin A and dihydromanumycin A were purchased 
from Adipogen Life Sciences and used without further purification. Man-A and its 
derivatives were reported by the manufacturer to be >95% pure by HPLC and 1H NMR. 
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Man-A and its derivatives were analyzed by HESI MS (Bruker Evo-Q Elite Triple-
Quadrupole) operating in positive ion mode and the anticipated m/z for M+1 was 
observed in all cases. Cytochrome c was purchased from Lee biochemical and superoxide 
dismutase was purchased from MP Biomedicals. Enzyme assay kit (fluorescent 
TrxR/Trx) and rat recombinant TrxR1 were purchased from Cayman Chemical. 
Mitochondrial TrxR and mutants, Drosophila melanogaster TrxR and mutants were gift 
from Dr. Robert Hondal from University of Vermnont. All other reagents were purchased 
from Sigma-Aldrich or Fisher Scientific and used without further purification. The 
TrxR/Trx assay was performed according to the kit manufacturer's instructions with noted 
exceptions below. UV-vis and fluorescence measurements were performed in 384 well 
microplates using a Synergy® 2 (BioTek Instrument, Inc.) or an Infinite® M1000 PRO 
(Tecan Group Ltd.) microplate reader. All assays were performed in triplicate. All assays 
were performed in triplicate. Results are presented as an average of three trials ±standard 
deviation. Error limits on graphs represent the standard deviation of three trials. 
3.5.1 DTNB reduction assay 
 
  (General DTNB reduction) The assay was performed in 384 well black flat 
bottom plates in a final volume of 100 μL. TrxR enzymes (6.4 nM or 7.04 nM) were 
reduced with NADPH (102 μM or 117 μM) in assay buffer (50 mM Tris-HCl, 1 mM 
EDTA pH 7.5) for 30 minutes at room temperature. Test compounds (0.625 mM in 25 % 
DMSO or MeOH) was added for a concentration of 25 μM. The mixture was incubated 
for an additional thirty minutes at room temperature. DTNB (20 μL, 10 mM in 0.1 M 
sodium phosphate and 1 mM EDTA, pH 8.0) was added to the TrxR/test compound 
mixture (80 μL) to initiate the reaction. Final concentrations: 5.12 nM or 5.6 nM TrxR; 
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20 µM test compound; 2 mM DTNB. The reduction of DTNB was monitored by 
measuring absorbance at 412 nm every 5 minutes for 1 hour. (Method A Pre-incubation 
with Man-A/test compounds. Rat recombinant TrxR1 (6.4 nM) was reduced with 
NADPH (102 μM) in assay buffer (50 mM Tris-HCl, 1 mM EDTA pH 7.5) for 30 
minutes at room temperature. The mixture was incubated for an additional thirty minutes 
with final Man-A concentration of 0, 5, 50, 500, 1800, 5000 nM. DTNB (20 μL, 10 mM) 
in 0.1 M sodium phosphate and 1 mM EDTA, pH 8.0 was added to 80 μL of reduced 
TrxR mixture and reduction of DTNB was monitored by measuring absorbance at 412 
nm every 5 minutes for 1 hour. (Method B) Without pre-incubation with Man-A. The 
assay was performed as described above except that Man-A and DTNB were added 
simultaneously after NADPH reduction of TrxR. All results are expressed as percent of 
control at termination (60 minutes). 
3.5.2 Standard curve for TNB2- 
 
 Standard curve for TNB2- was obtained by reducing DTNB with DTT (1,4-
dithiothreitol). Various concentration of DTT (0, 0.05 mM, 0.1 mM, 0.2 mM and 0.4 
mM) was prepared in 50 mM Tris-Cl, 1 mM EDTA pH 7.5. DTNB was prepared in 0.1 M 
sodium phosphate and 1 mM EDTA, pH 8.0. The production of TNB2- was measured at 
412 nm. 
3.5.3 Time course inhibition of DTNB reduction by TrxR  
 
 The assay was performed in 384 well black flat bottom plate in a final volume of 
100 μL. Rat recombinant TrxR1 (6.4 nM) was reduced with NADPH (102 μM) in assay 
buffer (50 mM Tris-HCl, 1 mM EDTA pH 7.5) for 30 minutes at room temperature. Man-
A (10 μL in 25% DMSO) was added for final concentrations of 1 μM and incubated for 
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15, 10, 5 and 2 min. DTNB (20 μL, 10 mM in 0.1 M sodium phosphate and 1 mM EDTA, 
pH 8.0) was added to the TrxR/Man-A (80 μL) to initiate the reaction. The reduction of 
DTNB was monitored by measuring absorbance at 412 nm every 5 minutes for 1 hour.  
 
3.5.4 Irreversible inhibition of TrxR  
 
 TrxR enzymes (80 nM) were reduced with NADPH (1.34 mM) in assay buffer (50 
mM Tris-HCl, 1 mM EDTA pH 7.5) for 30 minutes at room temperature. The reduced 
TrxR was divided into three aliquots viz. control (TrxR/no test compound), TrxR/ test 
compound and TrxR/test compound not subjected to gel filtration. A fourth of TrxR/ test 
compound solution was not reduced with NADPH. A solution of test compound (11 μL in 
25% DMSO) was added to the TrxR samples (280 μL) for concentrations of Man-A (2.6 
μM for TrxR1) and the other test compound (5.5 μM). The control sample was substituted 
with an equal volume of 25% DMSO instead of test compound solution. Samples were 
incubated for 1 hour at ambient temperature, after which they were passed through a 
Micro Bio-spin P-6 gel column of MW limit of 6000 (Bio-rad). One sample containing 
test compound was not passed through the gel filtration column. All samples (280 μL) 
were re-reduced with (20 μL, 1.34 mM) NADPH for 30 minutes. Finally, the DTNB 
assay was performed as described above by adding 20 μL of 10 mM DTNB to 80 μL of 
enzyme/ test compound mixture and the absorbance was monitored at 412 nm every 5 
minutes for 1 hour. Final concentrations: 5.2 nM TrxR, 2 μM Man-A for TrxR1, 4.2 μM 
for other test compounds. 
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3.5.5 TrxR/Trx insulin reduction 
 
 The assay was performed in 384 well black flat bottom plate in a final volume of 
100 μL.  Rat TrxR-1 (125 nM) was pre-reduced  for 30 min with NADPH (335 µM) in 
the presence of test compounds (25 μM) in assay buffer (0.2 mg/mL BSA, 50 mM Tris-
Cl, 1 mM EDTA pH 7.5). Human Trx (1 μM) was added for a Trx concentration of 125 
nM. This solution was incubated for an additional 30 minutes. Fluorescent substrate (20 
μL, 0.4 mg/mL, eosin labeled bovine insulin) was added to the enzyme/ test compound 
solution (80 μL) to initiate the reaction. Final concentrations: 100 nM TrxR; 20 μM test 
compounds; 100 nM hTrx-1. The fluorescence was monitored at λex/λem= 520nm/545 
nm every 5 minutes for 1 hour. Insulin reduction with mTrxR2 (CGUG) except the 
mTrxR2 (CGUG) and hTrx-1 concentrations were doubled.  
3.5.6 Reaction of Sel-green probe with seleno-L-cysteine 
 A stock solution of seleno-L-cystine (500 μL, 156 μM) was reduced with 1.5 
equivalent of immobilized TCEP (>8 μmol/mL) for 1 hour. After reduction, the 
immobilized TCEP was removed by centrifugation at 14,000 X g, for 10 minutes. The 
reduced L-selenocystiene (20 μL, 312 μM) was incubated with test compounds (10 μL, 
625 μM) for 1 hour. Sel-green (20 μL, 100 μM) was added to L-selenocysteine test 
compound mixture (80 μL) and fluorescence monitored at λex/λem= 370 nm/510 nm 
every 5 minutes for 1 hour. 
3.5.7 NADPH consumption by TrxR  
 
 The assay was performed in 384 well black flat bottom plates in a final volume of 
100 μL. NADPH (7.5 μL, 2.68 mM) in assay buffer (50 mM Tris-HCl, 1 mM EDTA pH 
7.5) was added to a solution (92.5 µL) of rat recombinant TrxR-1 or mTrxR2  or mutants 
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(0.21 μM) and Man-A (68 µM/42 µM) or test compounds (42 µM) in assay buffer and 
the absorbance was monitored at 340 nm for 30 minutes. Final concentrations: TrxR (0.2 
µM), Man-A (62.5 µM/38.5 µM), test compounds (38.5 µM), NADPH (200 µM). 
NADPH mol min/mol-enzyme was calculated from the standard curve of NADPH. 
3.5.8 Standard curve for NADPH 
 Standard curve for NADPH was obtained from calibration of NADPH of various 
concentrations (0, 50 μM, 100 μM, 250 μM and 500 μM) NADPH in 50 mM Tris-HCl, 1 
mM EDTA pH 7.5. The absorbance of NADPH was monitored at 340 nm. 
3.5.9 Superoxide radical anion production by TrxR in the presence of Man A 
 
  The NADPH oxidase activity induced by Man-A was determined by monitoring 
the reduction of cytochrome c by O2-. and measuring the absorbance of reduced 
cytochrome C at 550 nm. The assay was performed in 384 well black flat bottom plate in 
a final volume of 100 μL. Cytochrome c (10 μL, 1 μM), NADPH (7.5 μL, 2.68 mM), 
Man-A (2.5 μL, 2.5 mM/DMSO) or 2.5 μL DMSO were combined. The reaction was 
initiated by addition of rat TrxR1 (10 μL, 1 μM). The production of superoxide was 
confirmed by addition of 6 units SOD/well in parallel samples. SOD is used to quench 
superoxide generated by TrxR.  
3.5.10 Selenocystine reduction by TrxR1 and mTrxR variants 
 
 The assay was performed in a 384 well black flat bottom plates in a final volume 
of 100 μL. TrxR enzymes (25 nM) were reduced with NADPH (251 µM) in the presence 
of test compounds (48 μM) in assay buffer (in 50 mM Tris-HCl, 1 mM EDTA pH 7.5). 
The reaction was initiated by the addition of L-selenocystine (20 μL, 599 μM in assay 
buffer) to the enzyme test compound mixture (80 μL) either immediately or after 
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incubation for 15 minutes. Final concentrations: 20 nM TrxR; 38.5 μM test compound; 
120 μM selenocystine. The consumption of NADPH was monitored by measuring 
absorbance at 340 nm for 10 minutes.  
3.5.11 Reduction of hydrogen peroxide by TrxR1 and mTrxR2 (GCUG) 
 The assay was performed in a 384 well black flat bottom plate in a final volume 
of 100 μL. Hydrogen peroxide (20 μL, 250 mM) in assay buffer (50 mM Tris-HCl, 1 mM 
EDTA pH 7.5) was added to a solution (80 μL) of TrxR enzyme (62.5 nM), NADPH (200 
µM) and test compounds  (48 µM) in assay buffer, either immediately or after incubation 
for 15 minutes. Final concentrations: 50 nM TrxR; 38.5 μM test compound; 50 mM 
H2O2. The consumption of NADPH was monitored by measuring absorbance at 340 nm 
for 10 minutes. The potent TrxR inhibitor auranofin (38.5 μM) was used as a control. 
3.5.12 Preparation of cell lysate for biochemical assays 
 The human lymphoblast cell line (GM02152) was purchased from Coriell 
institute. Cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium 
supplemented with 15 % fetal bovine serum (FBS) and 2 μM sodium selenite and were 
maintained in a humidified incubator at 37°C and 5% CO2 until they reach log phase.  
For TrxR/Trx assay GM02152 cells were seeded in 75 cm2 flasks containing growth 
medium. The cells were harvested by centrifugation (720 X g, 4 minutes) when log phase 
was reached. The cells were lysed by addition of 100 μL lysis buffer (10 mM Tris-HCl, 
200 mM KCl, 2 mM EDTA, 40% glycerol, 0.2% TritonX-100, pH 7.5) followed by 
rotation at 4°C for 2 hours. Cellular debris was removed by centrifugation at 17000 X g 
at 4°C for 30 minutes. Protein concentration of the lysate was determined by the Bradford 
  67 
method using Coomassie protein assay reagent in triplicate. Typical concentration of the 
lysate ranged from 10-15 mg/ml.  
3.5.13 TrxR/Trx inhibition assay with cell lysate 
 
 The assay was performed in 384 well black flat bottom plate in a final volume of 
100 μL. Cell lysate (15.6 μg protein in lysis buffer) was reduced with NADPH (5 μL, 4 
mg/ml). Man-A (in 25% DMSO) was added for a final concentration of 1 μM. After 30 
minutes, human Trx (10 μL, 1 μM) was added and incubated for an additional 30 
minutes. Fluorescent substrate (20 μL, 0.4 mg/ml, eosin labeled bovine insulin) was 
added to the enzyme/Man-A solution (80 μL) to initiate the reaction. The fluorescence 
was monitored at λex/λem= 520nm/545 nm every 5 minutes for 1 hour.  
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Chapter 4. Effect of brevetoxin-2 and brevetoxin-3 on TrxR1, mTrxR and DmTrxR 
 
4.1 Objective 
 
 The activity of brevetoxin (PbTx) towards TrxR1 is unique in comparison to other 
known TrxR1 inhibitors. Both PbTx-2 and PbTx-3 activate reduction of DTNB by TrxR1. 
The insulin reduction assay reveals that PbTx-2 inhibits the reduction of Trx by TrxR1 in 
a dose-dependent manner but PbTx-3 has no effect. Because PbTx-2 has an α, β-
unsaturated side chain and PbTx-3 does not, the mechanism of inhibition was assumed to 
be the formation of a Michael adduct with the C-terminal redox site (Sec). However, the 
adduct of PbTx-2 and TrxR1 was not observed by mass spectroscopy. Hence the main 
objective of Chapter 4 is to understand the interaction between brevetoxins and TrxR in 
the activation of DTNB reduction and inhibition of Trx reduction. To accomplish this 
goal the site-specific mutant enzymes of mTrxR and DmTrxR will be used. The marine 
life exposed to red tide exhibit increased indicators of oxidative stress. The second 
objective of this chapter is to characterize indicatiors of oxidative stress in brevetoxin 
treated human lymphoblast cells and to determine if antioxidant treatments can mitigate 
the effect, whcih will be achieved by using a cellular model (human lymphoblast cells) 
and antioxidants, Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) and 
Vitamin C.  
 4.2 Introduction  
 
 Blooms of the famous Florida red tide, caused by the dinoflagellate K. brevis, are 
characterized by an obnoxious odor and dense red or brown patches near the water 
surface. This dinoflagellate exists naturally along the Gulf of Mexico and west coast of 
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Florida, blooming annually between late summer and fall. However, the bloom 
exacerbates as a result of some natural phenomenon such as increased water temperature, 
hurricane, floods etc.  Another possible bloom promoter is eutrophication related to an 
increase in nutrients such as phosphorus and nitrogen. Karenia brevis is well known for 
the production of neurotoxins known as the brevetoxins (PbTx) which may concentrate in 
shellfish and fishes that feed on these dinoflagellates. The harmful algal bloom (HAB) is 
accompanied by mortalities of marine mammals such as manatees and costal
species of fish and birds100 as a result of PbTx exposure. It also has detrimental impacts 
on human health and economies resulting from beach and shellfish bed closures. 
 Brevetoxins (PbTxs) are polycyclic polyether ladders. They can be differentiated 
into two distinct backbones type A and type B as shown in Figure 45101. The molecules 
have 10-11 fused rings and have a molecular weight around 900 Da. At least 12 different 
structures have been identified having different combinations of backbone and side 
chains and are designated from PbTx-1, 2, 3….102 as shown in Table 15. PbTx-2 with the 
B-type backbone is the most abundant while PbTx-1 with the A-type backbone is most 
potent103. 
 Brevetoxins are neurotoxins that can poison humans through ingestion of 
contaminated shellfish, inhalation of aerosolized toxin or through dermal exposure during 
swimming. A particular type of poisoning called Neurotoxic Shellfish Poisoning (NSP) is 
the result of consumption of shellfish contaminated with PbTxs. This poisoning is 
characterized by gastrointestinal and neurological symptoms such as nausea, vomiting, 
arrhythmias, ataxia, slurred speech and dizziness. Neurological symptom includes partial 
paralysis and respiratory distress 104. 
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 Brevetoxin A backbone          Brevetoxin B backbone  
Figure 45. PbTx structure 
 
Table 15. Side chain at K-ring of brevetoxin A and brevetoxin B 
 
Brevetoxin A 
Side chain at K-ring 
(R) Brevetoxin B 
Side chain at K-ring 
(R) 
PbTx-1 CH2C(=CH2)CHO PbTx-2 CH2C(=CH2)CHO 
PbTx-7 CH2C(=CH2)CH2OH PbTx-3 CH2C(=CH2)CHOH 
PbTx-10 CH2CH(CH3)CH2OH PbTx-5 [PbTx-2],C-38 OAc 
  PbTx-6 
[PbTx-2]27,28 ring 
epoxide 
  PbTx-8 CH2COCH2Cl 
  PbTx-9 CH2CH(CH3)CH2OH 
                                                                
 The biotransformation of PbTx in rat hepatocytes105, Porites astreoides106 and a 
monocyte cell line (U-937) has been a well-studied topic. Brevetoxin-1 and 2 form 
conjugates as Michael adducts, with glutathione and cysteine at the α, β-unsaturated 
aldehyde60. It is also oxidized by cytochrome P450107. A few studies have shown that 
PbTx induces oxidative stress in animals and cells. The indicators of oxidative stress 
include a decrease in intracellular glutathione108 in a monocyte cell line (U-937), reduced 
lymphocyte proliferation and decreased level of SOD (superoxide dismutase) in 
manatees60, DNA damage of human lymphocyte109 and Jurkat E6-1 cell line110.  
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4.3 Results and Discussion 
 
4.3.1 DTNB as a substrate for TrxR1  
 The DTNB reduction of TrxR1 is activated by 2.6-fold and 6-fold in presence of 
PbTx-2 and PbTx-3 respectively (Figure 46). In the case of PbTx-2, this activation of 
DTNB was attributed to modification of C-terminal tail of TrxR1 which allows DTNB to 
be reduced by the N-terminal redox center 63.  
    
Figure 46. DTNB reduction of TrxR1 in the presence of PbTx-2 (20 μΜ, ▲) and PbTx-3 (20 
μΜ, △); Control (○). Adapted from reference 63 
4.3.2 TrxR/Trx insulin reduction in the presence of PbTx-2 and PbTx-3 
 Brevetoxin-2 inhibits Trx reduction by TrxR1 and hence affects the reduction of 
insulin, while PbTx-3 has no effect (Figure 47). The inhibition of insulin reduction by 
TrxR1 in the presence of PbTx-2 was attributed to the covalent adduct formed by α, β-
unsaturated aldehyde group of PbTx-2 with Sec of TrxR1, which was further supported 
by the lack of inhibition by the allylic alcohol in PbTx-3.  
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Figure 47. Insulin reduction by TrxR/Trx system. (A) PbTx-2 (20 μΜ, ▲); (B) PbTx-3 (20 μΜ, 
△). Adapted from 63 
 
4.3.3 Reactivity of PbTx-3 with seleno-L-cysteine  
 
 Although PbTx-3 does not inhibit Trx reduction by TrxR1, it does react with 
selenocysteine (Figure 48) in a reaction monitored by release of fluorophore from Sel-
green probe93 In comparison to Sec of TrxR1, selenocysteine is a small molecule and 
could easily react with α, β-unsaturated lactone at A-ring of PbTx-3. Despite Sec in 
TrxR1 being a nucleophile, it is less available due to the large and complex nature of the 
enzyme causing steric hindrance.  
      
 
Figure 48. Reaction of reduced seleno-L-cysteine (20 μΜ) with Sel-green probe (20 μΜ) after 
incubation with the PbTx-3 (20 μΜ for 60 min) 
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4.3.4 DTNB as a substrate for mTrxR2 variants 
 
                  Both PbTx-2 and PbTx-3 induce activation of DTNB reduction by all mTrxR 
enzymes (Figure 49). As reported in Table 16, the highest degree of activation is observed 
with the dead tail mutant, mTrxR2 (GSSG) by 10-fold, which has a nonfunctional C-
terminal tail and reduction is only possible via the N-terminal redox center. The 
activation observed with the dead tail and truncated mutant also emphasize that these 
compounds does not necessarily have to interact with Sec for activation of DTNB 
reduction. Furthermore, the maximum activation of the dead tail mutant demonstrates 
that the brevetoxins act by exposing the N-terminal redox center.  
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Figure 49. Reduction of DTNB (2 mM) by mTrxR in the presence of PbTx-2 and PbTx-3 (20 
μΜ). (A) mTrxR2 (GCUG) (5.12 nM); (B) mTrxR2 (GCCG) (5.12 nM); (C) mTrxR2 (GSSG) 
(5.12 nM); (D) mTrxR∆8 (10 nM). The control sample was prepared by adding an equal volume 
of DMSO. PbTx-3 (△); PbTx-2(▲) and Control (○) 
Table 16. Enzyme activity expressed as TNB2- mol/min-mol enzyme for mTrxR control and 
activation of DTNB reduction reported as relative rate for PbTx-2 and PbTx-3 with respect to 
control. The consumption of DTNB was calculated from standard curve of TNB2- 
 
 mTrxR2 
(GCUG) 
mTrxR2 
(GCCG) 
mTrxR2 
(GSSG) 
mTrxR2 
(∆8) 
Control 785 ± 11.0 249 ± 23.2 226 ± 17.0 995 ± 65.5 
PbTx-3 3.25** 3.99** 10.07** 2.29** 
PbTx-2 1.37** 4.39** 9.06** 2.60** 
The number of asterisks indicate significant differences compared with control (** p <0.01) 
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4.3.5 DTNB as a substrate for DmTrxR variants 
 
 The activation observed in DmTrxR (Δ8) enzymes also accentuate that the C-
terminal Sec is not required for activation observed in DTNB reduction as shown in 
Figure 50. The enzyme activity increased in the presence of PbTx-2 and PbTx-3 as shown 
in Table 17. 
  
 
Figure 50. Reduction of DTNB (2 mM) by DmTrxR in the presence of PbTx-2 and PbTx-3 (20 
μΜ). (A) DmTrxRSCUG (10 nM); (B) DmTrxRSCCS (50 nM); (C) DmTrxR∆8 (10 nM). The 
control sample was prepared by adding an equal volume of DMSO. PbTx-3 (△); PbTx-2(▲) and 
Control (○) 
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Table 17. Enzyme activity expressed as TNB2- produced mol/min-mol enzyme for DmTrxR 
control and activation of DTNB reduction reported as relative rate for PbTx-2 and PbTx-3 with 
respect to control. The consumption of DTNB was calculated from standard curve of TNB2- 
 
 DmTrxR 
(SCUG) 
DmTrxR 
(SCCS) 
DmTrxR 
(∆8) 
Control 70.4 ± 2.25 34.5 ± 10.3 24.6 ± 5.03 
PbTx-3 2.97** 1.59* 2.12** 
PbTx-2 2.08** 1.26 2.69** 
The number of asterisks indicate significant differences compared with control (* p <0.05, ** p 
<0.01) 
 
4.3.6 Irreversible inhibition TrxR by PbTx-2  
  
 The C-terminal Cys and Sec of TrxR are both nucleophiles and can readily react 
with electrophilic α, β-unsaturated carbonyl of PbTx-2. In order to determine if the PbTx-
2 covalently formed an adduct with C-terminal redox center of TrxR, DTNB reduction 
was performed as usual with TrxR1, mTrxR2 (GCUG) and mTrxR2 (GCCG). However, 
after 1-hour incubation of pre-reduced TrxR1 with 4.2 M PbTx-2, the mixture was 
passed through a gel filtration column (MW cutoff of 6000 amu) followed by a 30 
minutes incubation with additional NADPH (Figure 51). The gel filtration should remove 
unbound PbTx-2 and the additional 30 minutes incubation should reestablish equilibrium. 
It is important to note that unlike Man-A, PbTx-2 at 4.2 M when passed through the gel 
filtration column did not activate DTNB reduction by any of the enzymes meaning that 
the interaction between the enzymes (TrxR1, mTrxR2 (GCUG) and mTrxR2 (GCCG)) 
and PbTx-2 is either non-covalent or reversible.  
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Figure 51. Test of irreversibility of inhibition of DTNB reduction by TrxR (5.2 nM) in the 
presence of PbTx-2 (4.2 μΜ). (A) TrxR1; (B) mTrxR2 (GCUG); (C) mTrxR2 (GCCG). TrxR 
reduced only after removal of test compounds by gel filtration ( ); Control (no test compound, 
○); Test compound removed by gel filtration after incubation with reduced TrxR1( ) 
4.3.7 Reactivity of TrxR1 and mTrxR variants with substrate selenocystine in the 
presence of PbTx-2 and PbTx-3 
 
 Reduction of selenocystine requires the C-terminal redox center with either 
Sec/Cys25 although the rate is much faster when Sec is present and uncompromised. The 
consumption of NADPH in the presence of selenocystine, is monitored as a proxy for 
selenocystine reduction. Comparison of the controls for Figure 52B, Figure 52C and 
Table 18 demonstrates that the mTrxR2 (GCCG) reduces selenocystine at a much slower 
rate than the wild type enzyme (Figure 52C) [mTrxR2 (GSSG) does not reduce 
selenocystine and was not included in this experiment]. Auranofin completely inhibited 
reduction of selenocystine which suggest it interacts at C-terminal redox site, possibly 
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Sec (Figure 52A). In the absence of pre-incubation, the reduction of selenocystine by 
TrxR is not compromised by both PbTx-2 and PbTx-3, as shown in Figure 52A, 
indicating the Sec residue of TrxR is available to reduce selenocystine.  
 
 
Figure 52. Reduction of selenocystine by TrxR (20 nM) in the presence of PbTx-2 and PbTx-3 
(38.5 μM) and auranofin (62.5 μM). (A) TrxR1; (B) mTrxR2 (GCUG); (C) mTrxR2 (GCCG). 
The number of asterisks indicate significant differences compared with control (* p <0.05, ** p 
<0.01) 
Table 18. Rates of of selenocystine reduction by TrxR enzymes in the presence of PbTx-2 and 
PbTx-3. NADPH consumption expressed as NADPH mol/min-mol enzyme 
  
TrxR1 
mTrxR2 
(GCUG) 
mTrxR2 
(GCCG) 
Control 1065 ± 150 794 ± 35.1 388 ± 142 
PbTx-2 1102 ± 78.4 657 ± 153 274 ± 4.43 
PbTx-3 1078 ± 81.6 929 ± 47.2** 290 ± 14.9 
The number of asterisks indicate significant differences compared with control (** p <0.01) 
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 On the other hand, the selenocystine reduction was enhanced by 1.2-fold by 
mTrxR2 (GCUG) and 1.6-fold by mTrxR2 (GCCG) in the presence of PbTx-2 after 
incubation for 15 minutes, as shown in Figure 53 and Table 19. The enhancement of 
selenocystine reduction also supports that Sec remains free while PbTx-2 might interact 
with Cys in a reversible manner. 
  
 
 
 
Figure 53. Reduction of selenocystine by TrxR (20 nM) after 15 minutes incubation with PbTx-2 
and auranofin (38.5 μM). (A) TrxR1; (B) mTrxR2 (GCUG); (C) mTrxR2 (GCCG). The number 
of asterisks indicate significant differences compared with control (* p <0.05, ** p <0.01) 
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Table 19. Rates of of selenocystine reduction by TrxR enzymes after 15 minutes incubation with 
PbTx-2 and auranofin. NADPH consumption expressed as NADPH mol/min-mol enzyme 
   
TrxR1 
mTrxR2 
(GCUG) 
mTrxR2 
(GCCG) 
Control  337 ± 80.5 347 ± 21.5 82.3 ± 18.8 
PbTx-2 408 ± 28.7 433 ± 19.6** 132 ± 14.7** 
Auranofin 15.2 ± 19.0** 1.67 ± 6.14** 8.00 ±8.35** 
The number of asterisks indicate significant differences compared with control (* p <0.05, ** p 
<0.01) 
4.3.8 Reactivity of TrxR1 and mTrxR2 (GCUG) with substrate hydrogen peroxide in 
the presence of PbTx-2 
 
 Brevetoxin-2 decreased the H2O2 reduction to 1.4-fold of that of mTrxR2 
(GCUG) control in absence of pre-incubation. The reduction of H2O2 requires the Sec 
residue to be free97-98 and the decrease with mTrxR2 (GCUG) signifies a non-covalent or 
reversible interaction of PbTx-2 withthe Sec residue. On the other hand, TrxR1 has no 
effect with as shown in Figure 54 and Table 20.  
  
 Figure 54. Hydrogen peroxide reduction by TrxR (50 nM) in the presence of PbTx-2 and 
auranofin (38.5 μM).  (A) TrxR1; (B) mTrxR2 (CGUG). The data is expressed as NADPH 
consumption during reduction of H2O2. The number of asterisks indicate significant differences 
compared with control (* p <0.05, ** p <0.01) 
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Table 20. Rate of H2O2 reduction by TrxR in the presence of PbTx-2. NADPH consumption 
expressed as NADPH mol/min-mol enzyme                       
 TrxR1 mTrxR2 (GCUG) 
Control 228 ± 6.84 341±8.20 
PbTx-2 235 ± 16.2 251± 35.6* 
Auranofin 12.89 ±7.29** 16.6 ±5.71** 
The number of asterisks indicate significant differences compared with control (* p <0.05, ** p 
<0.01) 
The hydrogen peroxide reduction was inhibited by 1.4-fold by TrxR1 and 
activated by 1.4-fold by mTrxR2 (GCUG) in the presence of PbTx-2 after incubation for 
15 minutes, as shown in Figure 55 and Table 21, corroborating the the non-covlent or 
reversible interaction of PbTx-2 with Cys. 
   
 
Figure 55. Hydrogen peroxide reduction by TrxR (50 nM) after 15 minutes incubation with 
PbTx-2 and auranofin (38.5 μM).  (A) TrxR1; (B) mTrxR2 (CGUG). The data is expressed as 
NADPH consumption during reduction of H2O2. The number of asterisks indicate significant 
differences compared with control (* p <0.05, ** p <0.01) 
 
Table 21. Rate of H2O2 reduction by TrxR after 15 minutes incubation with PbTx-2. NADPH 
consumption expressed as NADPH mol/min-mol enzyme        
 TrxR1 mTrxR2 (GCUG) 
Control 185 ± 21.1 235 ± 22.6 
PbTx-2 137 ± 11.5* 338 ± 4.89** 
Auranofin 11.1 ± 10.0** 27.9 ±29.9** 
  The number of asterisks indicate significant differences compared with control (* p <0.05, ** p 
<0.01)   
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4.3.9 NADPH oxidase activity of TrxR enzymes in the presence of PbTx-2 and PbTx-
3  
 
 Adduction of the C-terminal Sec residue on TrxR induces NADPH oxidase 
activity of TrxR49. The consumption of NADPH in the absence of disulfide or diselenide 
substrate is monitored as a proxy for production of ROS. The consumption of NADPH 
was monitored for TrxR1, mTrxR2 (GCUG), mTrxR2 (GCCG), mTrxR2 (GSSG) and 
mTrxR2 (Δ8) in the presence of PbTx-2 and PbTx-3. The NADPH consumption by, 
mTrxR2 (GSSG) and mTrxR2 (∆8) in the presence of PbTx-2 is increased by 25-fold, 
and 2.4-fold respectively when compared to their respective controls as listed in Table 22. 
On the other hand, PbTx-3 did not show an increase in NADPH consumption with any of 
the enzymes. 
Table 22. NADPH consumption by TrxR in the presence of PbTx-2 and PbTx-3. NADPH 
consumption expressed as NADPH mol/min-mol enzyme  
 
  
TrxR1 
mTrxR2 
(GCUG) 
mTrxR2 
(GCCG) 
mTrxR2 
(GSSG) 
mTrxR2 
(∆8) 
Control 1.13 ± 0.09 0.93 ± 0.14 0.40 ± 0.15 0.11 ± 0.04 0.49 ± 0.43 
PbTx-2 2.84 ± 1.63 1.17 ± 1.21 1.65 ± 1.24 2.80 ± 0.17** 1.18 ± 0.42* 
PbTx-3 - -0.88 ± 0.13 - - -1.29 ± 1.37 
The number of asterisks indicate significant differences compared with control (* p <0.05, ** p 
<0.01) 
4.3.10 Oxidative stress induced by PbTx-2 in GM02152 cells and use of antioxidants 
Trolox and ascorbic acid to mitigate the toxicity 
 
The red tide exposed loggerhead sea turtles61 and manatees60 were reported to 
show increases in indicators of oxidative stress in peripheral blood leukocytes. Human 
lymphoblast cells (GM02152) cells were evaluated for signs of oxidative stress induced 
by PbTx-2.  
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 Figure 56. Dose response curve for PbTx-2 for GM02152 cells by MTT assay after 24 hours of 
treatment 
 
The dose-response curve evaluated by MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-
diphenyltetrazolium bromide) assay shows that PbTx-2 has an EC50 value of 2.3 μM as 
shown in Figure 56. The use of antioxidant Trolox (6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid), water soluble version of vitamin E has been 
reported to mitigate the microcystin induced oxidative stress observed in tilapia111. The 
concentration of Trolox and Vitamin C (L-sodium ascorbate) used were 100 μM as no 
negative effect on the cells were observed at this concentration in MTT assay (Figure 57). 
 
 
Figure 57. MTT assay after antioxidants treatment for 24 hours. A. Trolox; B. Vitamin C 
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 Treatment of PbTx-2 (1 μM and 2 μM) in GM02125 cells for 24 hour reduced cell 
viability to 79 % and 55 % respectively of the untreated cells (Figure 58A). The 
simultaneous treatment of PbTx-2 (1 μM) and Trolox (100 μM) increased the cell 
viability to control levels. In comparison to Trolox treatment, vitamin C (100 μM) 
treatment was more effective at PbTx-2 concentration of 2 μM with cell viability of 98% 
(Figure 58B). The inhibition of TrxR will lead to an oxidized intracellular environment. 
Cellular glutathione level was reduced to 94% of the control for both PbTx-2 (1 μM) and 
PbTx-2/Trolox treatments. Free selenol content as determined from fluorescence probe 
Sel-green decreased to 89% and 87 % of control as shown in Figure 59A. The free radical 
can also degrade polyunsaturated fatty acid (PUFA) into lipid peroxide as reported in the 
larvae of coral Porites astreoides on exposure to K. brevis106.The lipid peroxide is 
unstable and degraded into aldehyde compounds the most common of which is 
malondialdehyde (MDA). MDA can be monitored using a thiobarbaturic acid (TBA) to 
form MDA-TBA adduct. On the other hand, lipid peroxidation increased to 105 % in 1 
μM PbTx-2 and 100 μM Trolox treated cell  (Figure 59A) When the GM02152 cells were 
treated with higher dose of PbTx-2 (2.5 μM) the selenol content was decreased to 85% of 
untreated cells without any effect on lipid peroxidation (Figure 59B). The vitamin C (100 
μM) treated sample has a free selenol content (87%) comparable to PbTx-2 (2 μM) 
treated samples (Figure 60).                                   
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Figure 58. Dose-response curve for GM02152 cells (A) PbTx-2 ◆; PbTx-2 and Trolox (100 μM, 
■) (B) PbTx-2 ◆; PbTx-2 and vitamin C (100 μM, ■). * indicates a statistically significant 
difference from the control (p≤ 0.05) 
  
Figure 59. Measurement of oxidative stress indicators in GM02152 cells after 24 hours treatment 
of PbTx-2 and Trolox. (A) PbTx-2 (1 μM) and Trolox (100 μM); (B) PbTx-2 (2.5 μM) and Trolox 
(100 μM). * indicates a statistically significant difference from the control (p≤ 0.05)                         
 
 
Figure 60. Measurement of oxidative stress indicators in GM02152 cells after 24 hours treatment 
of PbTx-2 (2 μM) and Vitamin C (100 μM). * indicates a statistically significant difference from 
the control (p≤ 0.05)   
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4.4 Conclusion 
 
 Compromising the C-terminal tail of TrxR can result in inactivation of the 
enzyme. Although both PbTx-2 and PbTx-3 can readily react with the amino acid 
selenocysteine as determined from the use of the Sel-green probe, only PbTx-2 inhibits 
Trx reduction by TrxR1. The inhibition of insulin reduction by TrxR1 in the presence of 
PbTx-2 suggests that the C-terminal redox center is compromised. The recovery of 
normal activity of TrxR1 after gel filtration suggests that the interaction between TrxR1 
and PbTx-2 is either reversible or non-covalent. Binding of PbTx-3 may induce positive 
allosteric regulation of TrxR as is observed with many enzyme inhibitor complex112 and 
thus the enzyme can still reduce substrates including insulin and selenocystine. The 
NADPH consumption by mTrxR2 (GSSG) in the presence of PbTx-2/PbTx-3 reveals that 
covalent modification of C-terminal redox center is not required for NADPH oxidase 
activity. Further, the activation of DTNB reduction with mTrxR variants as wells as 
DmTrxR variants occurs in a C-terminal Sec/Cys independent manner. 
 The reduction of selenocystine and H2O2 are more efficiently performed by Sec as 
compared to Cys95. In the presence of both the PbTx, the reduction of selenocystine is not 
compromised or partially compromised which reveals that these compounds may bind 
non-covalently or react reversibly with the C-terminal Cys which is available and is 
exposed to solvent rather than Sec26 when the enzyme is in the reduced-waiting position.  
On the other hand, PbTx-2 inhibits reduction of H2O2 by 1.4-fold of TrxR1 control. This 
result signifies the formation of a reversible Michael adduct. 
 The free selenol and thiol content of PbTx-2 treated GM02152 cells were lower as 
compared to the control. The treatment of cells with the antioxidant, Trolox did not have 
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significant efficacy for restoring the thiol/selenol content. However, vitamin C 
significantly enhanced cell viability, the thiol/selenol content and lipid peroxidation was 
similar to Trolox treatment.  
4.5 Materials and methods   
 2-Thiobarbituric acid (TBA) was purchased from MP biomedicals and 1,1,3,3- 
tetraethoxypropane (TEP) was purchased from Chem-Impex Int’l Inc.  
 DTNB reduction, reactivity with reduced selenocysteine, gel filtration, 
selenocystine, hydrogen peroxidase reduction and NADPH oxidase were performed 
according to procedure reported in section 3.5. All experiments are done in triplicate. 
4.5.1 Preparation of cell lysates for biochemical assays  
 GM02152 cells (2.5 × 107) were seeded in 75 cm2 flasks containing growth 
medium. After the cells reached log phase, growth medium was removed by 
centrifugation and replaced with fresh medium containing: 1 μM PbTx-2 or 1 μM PbTx-2 
+ 100 μM Trolox or DMSO alone. The cells were exposed for 24 hour after which they 
were resuspended in growth medium and centrifuged (720 ×g, 4 min). The supernatant 
was discarded, and the cells were lysed by the addition of 100 μL lysis buffer (10 mM 
Tris-HCl, 200 mM KCl, 2 mM EDTA, 40% glycerol, 0.2% TritonX-100, pH 7.5) by 
rotating at 4 °C for 2 hour as previously described. Cellular debris was removed by 
centrifugation at 17000 ×g at 4 °C for 30 min. Protein concentration of the lysate was 
determined by the Bradford method using the Coomassie protein assay reagent in 
duplicate. Typical concentrations of the lysate ranged from 10 to 15 mg/mL.  
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4.5.2 DTNB assay on cell lysates  
DTNB (100 μL, 5 mM in 0.1 M sodium phosphate, 1 mM EDTA pH 8) solution was 
added to the cell lysate (90 μg of total protein/well) and absorbance was measured 
immediately at 410 nm. The assay was performed in triplicate.  
4.5.3 Thiobarbituric acid-reactive substances (TBARS) assay on cell lysates  
Lipid peroxidation was determined by measuring the level of thiobarbituric acid-reactive 
substances (TBARS) in cells. Proteins were precipitated from the cell lysate (160 μg of 
total protein) by the addition of trichloroacetic acid (500 μL, 20%) followed by 
centrifugation at 14,000 × g for 15 min. To the supernatant thiobarbituric acid solution 
(500 μL of 0.67% in 10% DMSO) was added. The mixture was then heated for 15 min at 
90 °C. Absorbance was measured in triplicate at 532 nm.  
4.5.4 Sel green assay on cell lysates  
In a 96 well plate, Sel green probe (10 μL, 48 μM final concentration in 20% acetone in 
PBS) was added to cell lysate (75 μg of total protein/ well) to quantify the amount of 
selenocysteine. The mixture was incubated for 5 min and the fluorescence was measured 
at λex = 502 and λem = 370 nm. Each treatment was analyzed in triplicate.  
4.5.5 Statistical analysis of cytotoxicity and cell lysate assays 
 
All data values are given as mean ± standard error. ANOVA was per- formed by a Tukey 
Honestly Significant Difference test using the JMP 13.0.0 Software 
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Chapter 5. Effect of MC-LR and reduced MC-LR on TrxR1, mTrxR and DmTrxR 
variants 
 
5.1 Objective 
 
 Similar to PbTx-2, MCLR activates DTNB reduction by TrxR1. Most microcystin 
variants have a dehydroalanine residue within the peptide ring which could contribute to 
the formation of a Michael adduct with TrxR. The main objective of this chapter is to 
better understand the mechanism of activation of TrxR by microcystins which includes 
evaluation of the significance of the α, β-unsaturated carbonyl group in activation of 
DTNB reduction by TrxR. This goal will be accomplished by reducing the 
dehydroalanine of MC-LR with NaBH4. Further the reactivity of MCLR with Sec of 
TrxR will be evaluated by using mutants of mTrxR and DmTrxR.  
5.2 Introduction 
 
 Cyanobacteria are photosynthetic bacteria that are found in fresh, estuarine and 
marine waters. The cyanobacteria are prokaryotic and may produce cyanotoxins and 
some are also responsible for cyanobacterial harmful algal blooms (HABs). These algae 
are capable of forming blooms which can appear as a thick blue green mat like scum. The 
cause of the bloom is mainly a result of eutrophication. Phosphorus from agricultural land 
run-off to lakes and especially phosphorus promotes additional growth113. Cyanotoxins 
are broadly divided into neurotoxin like anatoxin-a(s) and saxitoxin, dermatoxin like 
lyngbyatoxin, and hepatoxin like nodularin, cylinderospermopsin, and microcystin. 
Toxins are released into the water when the algae die and cell wall break.  
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 Microcystins (MC’s) are cyclic heptapeptides as shown in Figure 61. About 80 
congeners of microcystin have already been identified. Most of the microcystins have 
five constant amino acids and two variable amino acids (X and Y as shown in Table 23. 
One of the abundantly found microcystin is microcystin-LR (MC-LR). LR is named for 
two variable amino acids leucine (L) and arginine (R) at the X and Y positions 
respectively. They also possess the characteristic long-chain, β-amino acid, called 
Adda (all-S, all-E)-3-amino-9-methoxy-2, 6,8-trimethyl-10-phenyldeca-4, 6-dienoic acid. 
   
    Figure 61. Microcystin LR 
  
Table 23. Microcystin and some of the most common congeners 
 
 
 
 
 
Name 
X-position 
amino acid 
Y-position amino 
acid 
Molecular weight 
(Dalton) 
Microcystin LA Leucine (L) Alanine (A) 910.06 
Microcystin YR Tyorosine (Y) Arginine (R) 1045.19 
Microcystin RR Arginine (R) Arginine (R) 1038.2 
Microcystin LR Leucine (L) Arginine (R) 995.17 
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5.3 Effect of microcystin in human health 
 
  Drinking water is the major route for toxin of exposure in the human body. 
Microcystins have been reported to be present in treated water114. This poses a major 
challenge for municipalities that use surface water as their drinking water source. Other 
routes can be food chain, ingestion or inhalation of contaminated water during recreational 
use. Once in the body, microcystin are carried to the liver cells by Organic Anion 
Transporting Polypeptides (OATP) where they covalently link to active cysteine residue of  
protein phosphatase 2A and protein phosphatase 1 in the cytosol115 and inhibit these 
enzymes. This enzyme cleaves phosphate groups from the proteins. As a result, 
phosphorylated proteins accumulate in the liver cell. Numerous physiological processes are 
regulated by phosphorylation and dephosphorylation of enzymes thus the inhibition of 
dephosphorylation disrupts cellular homeostasis. This is the primary mechanism of toxicity. 
However, like many inhibitors of TrxR, MC-LR also has the presence of α, β- unsaturated 
carbonyl in the dehydroalanine amino acid, which can serve as a Michael acceptor and 
inhibit the enzyme. The requirement of this functional group has been evaluated by reducing 
dehydroalanine of MC-LR. Further to understand if MC-LR interacts with Sec of TrxR site-
specific mTrxR and DmTrxR variants are used. 
5.4 Results and Discussion 
 
5.4.1 Reduction of MC-LR 
 
 The dehydroalanine in MC-LR, the site thought to be responsible for forming 
Michael adduct is reduced as previously described116  using NaBH4 for 96 hours as shown 
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in reaction in Figure 62. The completion of reduction was confirmed with MALDI-MS 
(Matrix Assisted Laser Desorption/Ionization-Mass spectrometry) as shown in Figure 63. 
 
 
Figure 62. Reduction of MC-LR. MC-LR (0.5 mg) reduced with freshly prepared NaBH4 in H2O 
(9ml, 1mg/ml) for 96 hours. The reduced MC-LR was cleaned with C-18 column and inspected 
with MALDI-MS. Adda moiety is represented as R 
 
 
Figure 63. MALDI-MS result for reduced MC-LR. The absence of m/z 995.55 peak which 
corresponds to M+1 of MC-LR and appearance of m/z at 997.576 (corresponding to M+1 of 
reduced MC-LR) represents the complete reduction of MC-LR  
 
5.4.2 Reactivity of MC-LR and reduced MC-LR with seleno-L-cysteine 
 
 The reactivity of MC-LR with reduced selenocysteine suggests that 
dehydroalanine of MC-LR could be the possible site for reactivity with Sec of TrxR. 
Reduced MC-LR fails to react with selenocystine. If the dehydroalanine is required for 
the activation of TrxR then we would predict that dihydro MC-LR would not avtivate 
TrxR (Figure 64). 
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Figure 64. Reaction of reduced seleno-L-cysteine (20 μΜ) with Sel-green probe (20 μΜ) after 
incubation with the MC-LR and dihydro MC-LR (20 μΜ for 60 min) 
 
5.4.3 DTNB as a substrate for TrxR1 and mTrxR variants 
 
 MC-LR activates DTNB reduction of TrxR1, mTrxR2 (GCUG), mTrxR2 (GCCG) 
and mTrxR2 (Δ8) by 3.3-fold, 2.9-fold, 2.3-fold and 4.2-fold respectively as shown in 
Figure 65 and Table 24. The DTNB reduction in the presence of dihydro MC-LR (Figure 
66) also exhibits the activation comparable to unreduced MC-LR. This fact emphasizes 
that MC-LR does not require a dehydroalanine for activation of DTNB reduction by 
TrxR. This fact is further supported by activation of DTNB reduction in the presence of 
MCLR by the dead tail and truncated mutants of mTrxR, neither of which has a C-
terminal active site Cys or Sec. 
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Figure 65. Reduction of DTNB (2 mM) by TrxR in the presence of MC-LR (20 μM). (A) TrxR1 
(5.12 nM); (B) mTrxR2 (GCUG) (5.12 nM); (C) mTrxR2 (GCCG) (5.12 nM); (D) mTrxR2 
(GSSG) (5.12 nM); (E) mTrxR2 (∆8) (10 nM). MC-LR (◇). Control (DMSO only, ○). 
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Table 24. Enzyme activity expressed as TNB2- mol/min-mol enzyme for TrxR control and 
activation of DTNB reduction reported as relative rate for MC-LR and dihydro MC-LR with 
respect to control. The consumption of DTNB was calculated from standard curve of TNB2- 
 
 
 
TrxR1 
mTrxR2 
(GCUG) 
mTrxR2 
(GCCG) 
mTrxR2 
(GSSG) 
mTrxR2 
(∆8) 
Control 634 ± 47.3 785 ± 11.0 249 ± 23.2 226 ± 17.0 995 ± 65.5 
MC-LR 3.32** 2.90** 2.25** 4.21** 2.42** 
Dihydro MC-
LR 
3.55** 0.89** 0.99 1.27 1.14 
The number of asterisks indicate significant differences compared with control (** p <0.01) 
 
Figure 66. Reduction of DTNB (2 mM) by TrxR1 (5.12 nM) in the presence of dihydro MC-LR 
(20 μM, ▲) and MC-LR. (20 μM, ◇); Control (DMSO only, ○) 
 
 
5.4.4 DTNB as a substrate for DmTrxR variants 
 
 MC-LR activates DTNB reduction of DmTrxR (SCUG) and DmTrxR (Δ8) by 
1.7-fold and 2.5-fold respectively as shown in Figure 67 and Table 25. 
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Figure 67. Reduction of DTNB (2 mM) by DmTrxR in the presence of MCLR (20 μM). (A) 
DmTrxRSCUG (10 nM); (B) DmTrxRSCCS (50 nM); (C) DmTrxR (∆8) (10 nM). MCLR (◇); 
Control (DMSO only, ○) 
Table 25. Enzyme activity expressed as TNB2- mol/min-mol enzyme for DmTrxR control and 
activation of DTNB reduction reported as relative rate for MC-LR with respect to control. The 
consumption of DTNB was calculated from standard curve of TNB2- 
 
 DmTrxR 
(SCUG) 
DmTrxR 
(SCCS) 
DmTrxR 
(Δ8) 
Control 70.4 ± 2.25 34.5 ± 10.3 24.6 ± 5.03 
MC-LR 1.68** 1.15 2.49** 
The number of asterisks indicate significant differences compared with control (** p <0.01) 
5.4.5 Irreversible inhibition TrxR by MC-LR 
 In order to determine if the MC-LR covalently formed an adduct with the C-
terminal redox center of TrxR, DTNB reduction was performed as usual with TrxR1, 
mTrxR2 (GCUG) and mTrxR2 (GCCG) incubated with MCLR (4.2 M) after size 
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exclusion chromatography to remove unbound MCLR. After incubation, the mixture was 
passed through a gel filtration column (MW cutoff of 6000 amu) followed by a 30 min 
incubation with additional NADPH to reduce TrxR (Figure 68). The reduction of DTNB 
by TrxR enzymes incubated with MC-LR as well as TrxR reduced only after passing 
through size exclusion column was not activated in any of the enzymes, revealing either 
non-covalent or reversible covalent interaction between the enzymes (TrxR1, mTrxR2 
(GCUG) and mTrxR2 (GCCG)) and MC-LR.  Such interaction is not possible with dead 
tail and truncated enzyme due to lack of C-terminal active site.   
   
 
Figure 68. Test of irreversibility of inhibition of DTNB reduction by TrxR in the presence of 
MC-LR (4.2 μΜ). (A) TrxR1 (5.2 nM); (B) mTrxR2 (GCUG) (5.2 nM); (C) mTrxR2 (GCCG) 
(5.2 nM). TrxR reduced only after removal of activator/test compounds by gel filtration ( ); 
Control (no MC-LR, ○); MC-LR removed by gel filtration after incubation with reduced TrxR 
( ) 
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5.4.6 TrxR/Trx insulin reduction in the presence of MC-LR 
 
 Neither MC-LR nor reduced MC-LR inhibit insulin reduction by TrxR, which 
support the hypothesis that these compounds either non-covalently or irreversibly interact 
with TrxR (Figure 69). 
     
 
Figure 69. TrxR1/Trx reduction in the presence of MC-LR (◇, 20 μΜ) and dihydro MC-LR (■, 
20 μΜ). 
 
5.4.7 Reactivity of TrxR1 and mTrxR variants with substrate selenocystine in the 
presence of MC-LR  
 
 Unlike auranofin, the reduction of selenocystine is not compromised in the 
presence of MC-LR. The reduction of selenocystine requires a C-terminal redox site. 
Mutation of  the C-terminal Sec to Cys  reduces the rate of selenocystine reduction by 5-
fold 25. As shown in Figure 70 and Table 26, a comparison of the selenocystine reduction 
in the presence of MC-LR by all enzymes reveals that Sec remains free to reduce 
selenocystine when not pre-incubated with reduced TrxR.  
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Figure 70. Reduction of selenocystine (120 μM) by TrxR (20 nM) in the presence of MC-LR and 
auranofin (38.5 μM); (A) TrxR1; (B) mTrxR2 (GCUG); (C) mTrxR2 (GCCG).  The number of 
asterisks indicate significant differences compared with control (* p <0.05, ** p <0.01) 
Table 26. Rates of selenocystine reduction by TrxR enzymes in the presence of MC-LR. NADPH 
consumption expressed as NADPH mol/min-mol enzyme 
TrxR1 
mTrxR2 
(GCUG) 
mTrxR2 
(GCCG) 
Control 1065 ± 150 794 ± 35.1 388 ± 142 
MC-LR 935 ± 87.8 563 ± 69.9** 250 ± 12.8 
The number of asterisks indicate significant differences compared with control (* p <0.05, ** p 
<0.01) 
As shown in Figure 71 and Table 27, the selenocystine reduction after incubation 
(15 minutes) of MC-LR with reduced TrxR resulted in decrease of 1.3-fold in the 
presence of MC-LR as compared to mTrxR2 (GCUG) control. On the other hand, 
auranofin completely inhibited the reduction of selenocystine either incubated with MC-
LR or not with all the enzymes. 
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Figure 71. Reduction of selenocystine (120 μM) by TrxR (20 nM) after 15 minutes incubation 
with MC-LR and auranofin (38.5 μM); (A) TrxR1; (B) mTrxR2 (GCUG); (C) mTrxR2 (GCCG). 
The number of asterisks indicate significant differences compared with control (* p <0.05, ** p 
<0.01) 
Table 27. Rates of selenocystine reduction by TrxR enzymes after 15 minutes incubation with 
MC-LR. NADPH consumption expressed as NADPH mol/min-mol enzyme 
  
TrxR1 
mTrxR2 
(GCUG) 
mTrxR2 
(GCCG) 
Control 337 ± 80.5 347 ± 21.5 82.2 ± 18.8 
MC-LR 331 ± 28.1 275 ± 11.9** 127 ± 41.5 
Auranofin 15.2 ± 19.0** 1.67 ± 6.14** 8.00 ±8.35** 
The number of asterisks indicate significant differences compared with control (* p <0.05, ** p 
<0.01) 
 
5.4.8 Reactivity of TrxR1 and mTrxR2 (GCUG) with substrate hydrogen peroxide in 
the presence of MC-LR 
 
In the presence of MC-LR, hydrogen peroxidase activity was not compromised as 
shown in Figure 72 and Table 28. Reduction of H2O2 requires C-terminal Sec97-98. The 
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result presented below shows that MC-LR does not interact with Sec in absence of pre-
incubation. 
Figure 72. Hydrogen peroxide reduction by TrxR (50 nM) in the presence of MC-LR and 
auranofin (38.5 μM). (A) TrxR1; (B) mTrxR2 (CGUG). The data is expressed as NADPH 
consumption during reduction of H2O2. The number of asterisks indicate significant differences 
compared with control (* p <0.05, ** p <0.01) 
Table 28. Rate of H2O2 reduction by TrxR in the presence of MC-LR and auranofin. NADPH 
consumption expressed as NADPH mol/min-mol enzyme     
TrxR1 
mTrxR2 
(GCUG) 
Control 228± 6.84 341± 8.20 
MC-LR 239 ± 12.36 406±114 
Auranofin 12.89 ±7.29** 16.6 ±5.71** 
The number of asterisks indicate significant differences compared with control (* p <0.05, ** p 
<0.01) 
MC-LR induced 1.4-fold increase in H2O2 reduction as compared to mTrxR2
(GCUG) control when incubated for 15 minutes, as shown Figure 73 and Table 29 while 
no significant change is observed with TrxR1. 
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Figure 73. Hydrogen peroxide reduction by TrxR (50 nM) after 15 minutes incubation with MC-
LR and auranofin (38.5 μM). (A) TrxR1; (B) mTrxR2 (CGUG). The data is expressed as NADPH 
consumption during reduction of H2O2. The number of asterisks indicate significant differences 
compared with control (* p <0.05, ** p <0.01) 
Table 29. Rate of H2O2 reduction by TrxR after 15 minutes incubation with MC-LR and 
auranofin. NADPH consumption expressed as NADPH mol/min-mol enzyme  
    
  
TrxR1 
mTrxR2  
(GCUG) 
Control 185 ± 21.0 235 ± 22.6 
MC-LR 165 ± 13.4 339± 3.12** 
Auranofin 11.1 ± 10.0** 27.9 ±29.9** 
The number of asterisks indicate significant differences compared with control (* p <0.05, ** p 
<0.01) 
5.4.9 NADPH oxidase activity of TrxR enzymes in the presence of MC-LR  
 
 Modification of the C-terminal Sec of TrxR by alkylation or coordination with a 
noble metal induces the NADPH oxidase activity of TrxR 49. This can be measured by 
monitoring NADPH consumption in the absence of a disulfide or diselenide substrate. In 
the presence of MC-LR, NADPH consumption by TrxR1 increased by 1.3-fold as 
compared to controls as listed in in Table 30.  
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Table 30. NADPH consumption by TrxR in the presence of MC-LR (38.5 μΜ). NADPH 
consumption expressed as NADPH mol/min-mol enzyme 
TrxR1 
mTrxR2 
(GCUG) 
mTrxR2 
(GCCG) 
mTrxR2 
(GSSG) 
mTrxR2 
(Δ8) 
Control 3.63 ± 3.37 0.93 ± 0.14 0.40 ± 0.15 0.55 ± 0.40 0.49 ± 0.43 
MCLR 4.82 ± 5.49 1.27 ± 0.24 0.72 ± 0.66 0.39 ± 0.09 0.85 ± 1.07 
The number of asterisks indicate significant differences compared with control (* p <0.05, ** p 
<0.01) 
5.5 Conclusion 
The summary of all the enzymatic assays in the presence of MC-LR is given in 
Table 31. 
Table 31. Summary of TrxR activity in the presence of MC-LR 
TrxR1 
mTrxR2 
(GCUG) 
mTrxR2 
(GCCG) 
mTrxR2 
(GSSG) 
mTrxR2 
(Δ8) 
DΤΝΒ 
reduction 
Activate Activate Activate Activate Activate 
Insulin 
reduction 
No inhibition - - - - 
DTNB 
reduction 
after size 
exclusion 
No activation No activation No activation - - 
NADPH 
oxidase 
No activation No activation No activation No activation No activation 
Selenocystine 
reduction 
No activation Inhibit No activation No activation No activation 
Selenocystine 
reduction (15 
minutes 
incubation) 
No activation Inhibit No activation - - 
H2O2 
reduction 
No activation No activation - - - 
H2O2 
reduction (15 
minutes 
incubation) 
No activation Activate - - -
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 MC-LR activates DTNB reduction with all the enzymes tested. On the other hand, 
reduced MC-LR that does not have α, β-unsaturated carbonyl group activates DTNB 
reduction by TrxR1 while it has little effect on the other enzymes. Failure to inhibit 
selenocystine reduction and failure to activate DTNB reduction after removal of MC-LR 
by size exclusion also indicates that the interaction between TrxR and MC-LR is either 
non-covalent or reversible. Further this hypothesis is supported by the failure of both 
MC-LR and reduced MC-LR to inhibit insulin reduction in a Trx dependent reaction.   
5.6 General experiment   
 
 Microcystin-LR was purified from biomass collected during an algae bloom117 
according to published protocols116. Dihdro MC-LR was prepared according to published 
methods118 and analyzed by MALDI-MS. The Sel-green probe was synthesized according 
to published methods93 . All assays were performed in triplicate. Results are presented as 
an average of three trials ±standard deviation. Error limits on graphs represent the 
standard deviation of three trials. 
  DTNB reduction, reactivity with reduced selenocysteine, gel filtration, 
selenocystine, hydrogen peroxidase reduction and NADPH oxidase were performed 
according to procedure reported in section 3.5 
5.6.1 Preparation, purification and analysis of dihydro MCLR  
 
The dehydroalanine of MC-LR (0.5 mg, 0.5 µmol) was reduced with 0.23 mmol 
of freshly prepared NaBH4 in H2O for 96 hours. Fresh batch of NaBH4 (500 µL) was 
added every 6 hours.  
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The reduced MC-LR was separated from inorganic by-products using a C-18 SPE 
column (10 gm). The SPE column was conditioned ith 100 ml of MeOH (followed by 
100 ml distilled H2O. The reduced sample was loaded in the column and washed with 
100 ml of H2O to remove the impurities. Finally, the reduced MC-LR was eluted with 50 
ml of 100% MeOH and reconstituted in 1 mg/ml final concentration. 
MALDI-TOF-MS analysis was conducted on a Bruker AutoFlex III instrument, 
utilizing the dried droplet technique. The instrument was operated in the reflectron mode 
and positive (+) ion polarity. The sample was diluted in a 1:10 ratio with 50/50 
H2O:MeCN, before being mixed in a 1:1 ratio with a matrix solution composed of α-
cyanno-4-hydroxycinnamic acid (α-CHCA) in a solvent system consisting of 50/50 
H2O:MeCN with 0.5% TFA. For Reduced MCLR, mass spectrometry analysis detected a 
peak at m/z =997.576 with a mass error of + 4.32 ppm corresponding to the theoretical 
m/z = 997.572 for the [M+H] + ion of formula C49H76N10O12. In addition, a peak was 
observed at m/z = 1019. 596 with a mass error of + 9.8 ppm with respect to the theoretical 
m/z = 1019.554 for the [M+Na]+ for formula C49H76N10O12. Other ions were also detected 
at m/z = 1015.596, 1031.583, 1037.536, 1041.541, and 1063.540.  
5.6.2 DTNB reduction with reduced MC-LR 
The DTNB reduction with reduced MC-LR is performed in the similar way as 
regular DTNB assay, refer to Section 3.5.1. The concentration of reduced MC-LR was 
estimated form absorption of the Adda group at 238 nm by comparing with standard 
unreduced MC-LR. The control sample has an equal amount of DMSO.  
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Chapter 6. Effect of antibiotics on TrxR1, mTrxR and DmTrxR 
6.1 Objective 
Manumycin, an antitumor compound with several α, β-unsaturated carbonyl 
moieties is a potent inhibitor of TrxR1 and induce apoptosis by generating ROS. The 
effect of antibiotics (Ga, Rf and Th) with similar electrophilic functional groups on TrxR 
will be studied in this chapter using WT and mutants of mTrxR and DmTrxR.  
6.2 Introduction 
Geldanamycin (Ga) and rifamycins are bacterial ansamycin antibiotics that have 
aromatic group linked by an aliphatic chain. Ga binds to highly conserved pocket of heat 
shock protein  90 (Hsp90) and inhibit the enzyme119. Hsp are a family of chaperone 
proteins that regulates many critical functions in cells including refolding, protein 
stabilization120-121and indirectly controling apoptosis by inhibiting caspsase122. HSP is 
upregulated in numerous cancer and tumor cells123-124 because of which it has been a 
primary target for cancer treatment125-131.  
The rifamycin class includes derivatives of rifamycin including rifamycin SV 
(Rf). The family of rifamycin drug has been effective in treatment of disease involving 
bacteria mycobacterium and act by inhibiting bacterial RNA polymerase132 . Rifamycins 
have multiple targets including transcriptional repression protein BCL6 (B cell 
lymphoma 6 protein)133 and  organic anion transporting polypeptide134. 
Th, a naturally occurring antibacterial oligopeptide that inhibits bacterial protein 
synthesis by binding to ribosomal RNA but does not affect eukaryotic protein 
synthesis135. It is also an inhibitor of peroxiredoxin (Prx 3) an important scavenger of 
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H2O2 and lipid peroxide, and is upregulated in cancerous cell136. As the result of 
inhibition of peroxiredoxin, FOXM1 (Forkhead box M1) an important oncogenic 
transcription factor137 is downregulated. 
 Cancer cells treated with these antibiotics have been known to produce ROS. The 
napthohydroquinone of Rf and quinione of Ga can accept one or two electrons from 
NADPH and undergo oxidation or reduction in the presence of appropriate reductase and 
dehyrogenases. Rf can undergo redox recycling in the presence of NADPH/NADH, rat 
liver microsomes and Fe catalyst138 to produce .OH, H2O2 and O2-. radical. Similarly, one 
electron reduction of Ga by cytochrome P450 reductase in the presence of NADPH 
produces O2-. radical 139-140. The O2-. radical has been reported to be produced in 
malignant mesothelioma cells as a result of  Prx3 inhibition by Th137.  
6.3 Results and Discussion 
 
6.3.1 Reactivity of antibiotics with seleno-L-cysteine 
 
The reactivity with reduced selenocysteine in the reaction monitored by release of 
fluorophore from Sel-green probe93 indicates all the antibiotics may react with TrxR, as 
shown from Figure 74. 
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Figure 74. Reaction of reduced seleno-L-cysteine (20 μΜ) with Sel-green probe (20 μΜ) after 
incubation with the Ga, Rf and Th (20 μΜ for 60 min) 
 
 
6.3.2 DTNB as a substrate for TrxR1 and mTrxR variants 
 
 Ga, Rf and Th activates the reduction of DTNB by TrxR1, mTrxR2 (GCUG), 
mTrxR2 (GCCG) and mTrxR2 (Δ8) as shown in Figure 75 and Table 32. 
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Figure 75. Reduction of DTNB (2 mM) by TrxR (5.12 nM) in the presence of Ga; Rf and Th (20 
μM). (A) TrxR1; (B) mTrxR2 (GCUG); (C) mTrxR2 (GCCG); (D) mTrxR2 (GSSG); (E) 
mTrxR2 (∆8). Ga (◆); Rf (●); Th (□) and Control (DMSO only, ○) 
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Table 32. Enzyme activity expressed as TNB2- mol/min-mol enzyme for TrxR control and 
activation of DTNB reduction reported as relative rate for Ga, Rf and Th with respect to control.  
 
 
 
TrxR1 
mTrxR2 
(GCUG) 
mTrxR2 
(GCCG) 
mTrxR2 
(GSSG) 
mTrxR2 
(∆8) 
Control 634 ± 47.3 785 ± 11.0 249 ± 23.2 226 ± 17.0 995 ± 65.5 
Ga 2.67** - - - - 
Rf 2.33** 1.96** 1.53** 1.82** 2.01** 
Th 2.35** 3.04** 2.40** 4.42** 
2.37** 
 
The number of asterisks indicate significant differences compared with control (** p <0.01) 
 
6.3.3 DTNB as a substrate for DmTrxR variants 
 
Ga, Rf and Th activate the DTNB reduction of DmTrxR (SCUG), DmTrxR 
(SCCS) and DmTrxR (Δ8) as shown in Figure 76 and Table 33. 
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Figure 76. Reduction of DTNB (2 mM) by DmTrxR in the presence of Rf and Th (20 μΜ). (A) 
DmTrxRSCUG (10 nM); (B) DmTrxRSCCS (50 nM); (C) DmTrxR∆8 (10 nM). The control 
sample was prepared by adding an equal volume of DMSO. Rf (20 μM, ●); Th (20 μM, □) and 
Control (DMSO only, ○) 
Table 33. Enzyme activity expressed as TNB2- mol/min-mol enzyme for DmTrxR control and 
activation of DTNB reduction reported as relative rate for Ga, Rf and Th with respect to control.  
DmTrxR 
(SCUG) 
DmTrxR 
(SCCS) 
DmTrxR 
(Δ8) 
Control 70.4 ± 2.25 34.5 ± 10.3 24.6 ± 5.03 
Rf 1.32** 1.44* 2.64** 
Th 1.03 1.02 1.13** 
The number of asterisks indicate significant differences compared with control (* p <0.05, ** p 
<0.01) 
6.3.4 Reduction of DTNB by TrxR1 in the simultaneous the presence of curcumin 
and antioxidants  
The TrxR is known to react with the residue of TrxR1. Competition assays with 
C-terminal Sec two inhibitor inhibitor curcumin and the test compounds for TrxR1 could
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help to isolate the site of interaction. When TrxR1 was incubated first with curcumin (20 
μΜ, 30 minutes) followed by either Ga, Rf or Th (20 μΜ, 30 minutes), DTNB reduction 
was comparable to the curcumin only, as shown in Table 34 (not significantly different). 
When TrxR1 was incubated with the test compounds first followed by curcumin, the Ga, 
Rf and Th treated enzyme remains active (336, 289 and 154% of the curcumin control 
respectively). The thiostrepton treated samples retain about 50% of the original enzyme 
activity. The pre-treatment of TrxR1 with three of the test compounds, Ga, Rf and Th 
prevented the curcumin induced inhibition of DTNB reduction by TrxR1 suggesting 
competition for the same site. 
Table 34. Initial rates (V0) of DTNB reduction in the presence of the test compounds (20 μM) vs 
curcumin (20 μM) relative to the control. Control rate; 634 ± 47.2 mole TNB2-/min-mol TrxR 
Curcumin first Curcumin second 
Curcumin only 0.01 0.01 
Ga 1.22 3.36 
Rf 0.22 2.89 
Th 0.2 1.54 
6.3.5 TrxR1/Trx insulin reduction in the presence of antioxidants 
None of the antibiotics inhibit insulin reduction by TrxR1(Figure 77) which is 
contradicting as in the competition with curcumin added second, these compounds still 
showed activation (Section 6.3.4). The possibility of reversible or non-covalent 
interaction with C-terminal redox site of TrxR1 could explain the observed reduction of 
insulin.   
The other possibility of such result would be if the interaction of antibiotics with 
TrxR1 would expose N-terminal thiols. The reduced thiol could then reduce the insulin (6 
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kDa) directly without reduction of large Trx (11.7 kDa) In order to evaluate this 
hypothesis, insulin reduction assay was performed in absence of hTrx-1. As shown in 
Figure 78, in the absence of hTrx-1 and the presence of Ga (20 μM) the reduction of 
insulin is prevented which suggest that   insulin reduction only occurs via reduced hTrx-
1. 
 
 
Figure 77. TrxR1/Trx reduction in the presence of Rf and Th (20 μM). Rf (●); Th (□) and control 
(DMSO only, ○) 
 
 
 
Figure 78. TrxR1/Trx inhibition in the absence of hTrx-1and in the presence of Ga (20 μΜ). Ga 
(×); Control (○); Ga without hTrx-1 (▲). Data expressed as % of control at 60 min. 
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6.3.6 Native PAGE gel for determination of disruption of TrxR1 by Ga 
Ladder shaped polyether compounds like desulfated yessotoxin and brevetoxin-2 
are known to interact with the α-helix and disrupt the oligomeric glycophorin A, a 
transmembrane protein in erythrocytes141. If disruption of TrxR1 is induced by these 
compounds each monomer could reduce DTNB via the N-terminal redox center, by-
passing the C-terminal redox center, and might explain the result observed with DTNB 
reduction. Similar result of enhanced activity has been reported as the result of 
acetylation of TrxR1 at Lys141, Lys200 and Lys307 which increases the population of active 
dimeric TrxR1142.  A native PAGE gel (as SDS is known to disrupt TrxR dimers)143 was 
run to test this hypothesis. The disruption of the TrxR dimer should result in monomeric 
band at 55 kDa. The comparison of control and Ga treated TrxR in a native gel is shown 
in Figure 79. This result demonstrates that Ga does not disrupt TrxR1 dimers which 
contradict the original hypothesis. 
Figure 79. Native PAGE for determination of disruption of TrxR1 by Ga. Rat recombinant TrxR1 
(4.7 μg) was incubated with (2.5 mM) Ga for an hour. The control sample have equivalent 
amount of DMSO.  
6.3.7 Reactivity of TrxR1 and mTrxR variants with substrate selenocystine in the 
presence of antibiotics 
As shown in Figure 80 and Table 35, TrxR enzymes are not inhibited in the 
presence of these antibiotics and the rates are either comparable to or higher than the 
respective controls. In the presence of Ga and Rf, the selenocystine reduction increased 
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by 1.6-fold and 1.4-fold as compared to mTrxR2 (GCUG) control while Rf and Th 
induced 1.7-fold and 1.7-fold of activation of selenocystine reduction when compared to 
mTrxR2 (GCCG) control. Because this reaction is faster when there is a free selenol in 
the C-terminal redox center, this resut suggests involvement of Sec in reduction of 
selenocystine which could only be possible when these antibiotics react non-covalently or 
reversible with enzymes. 
Figure 80. Reduction of selenocystine by TrxR (20 nM) in the presence of Ga; Th; Rf (38.5 μM) 
and auranofin (62.5 μM). (A) TrxR1; (B) mTrxR2 (GCUG); (C) mTrxR2 (GCCG). The number 
of asterisks indicate significant differences compared with control (* p <0.05, ** p <0.01) 
0
200
400
600
800
1000
1200
1400
Control Ga Rf Th Auranofin
N
A
D
P
H
 m
o
l/
m
in
-m
o
l 
e
n
z
y
m
e
A
**
0
200
400
600
800
1000
1200
1400
Control Ga Rf Th
N
A
D
P
H
 m
o
l/
 m
in
-m
o
l 
e
n
z
y
m
e
B
** **
0
200
400
600
800
1000
1200
1400
Control Ga Rf Th
N
A
D
P
H
 m
o
l/
m
in
-m
o
l
e
n
z
y
m
e
C
**
  116 
Table 35. Rates of of selenocystine reduction by TrxR enzymes in the presence of Ga, Rf, 
auranofin and Th with respect to control. NADPH consumption expressed as NADPH mol/min-
mol enzyme 
  
TrxR1 
mTrxR2 
(GCUG) 
mTrxR2 
(GCCG) 
Control 1065 ± 150 794 ± 35.1 388 ± 142 
Ga 1042 ± 80.8 1278 ± 141** 527 ± 14.4 
Rf 1261 ± 80.6 1110 ± 193** 665 ± 20.4* 
Th 1233 ± 82.3 865 ± 208 652 ± 49.0* 
The number of asterisks indicate significant differences compared with control (* p <0.05, ** p 
<0.01) 
As shown in Figure 81 and Table 36, the selenocystine reduction after incubation 
(15 minutes) of Ga, Rf and Th with reduced TrxR resulted in increase of 1.5-fold in the 
presence of Th as compared to TrxR1 control. Similarly, Ga, Rf and Th induced 1.2-fold, 
1.2-fold and 1.6-fold as compared to mTrxR2 (GCUG) control respectively while only Th 
induced 2.5-fold increase in selenocystine reduction as compared to mTrxR2 (GCCG) 
control. On the other hand, auranofin completely inhibited the reduction of selenocystine 
either incubated with antioxidants or not with all the enzymes. 
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Figure 81. Reduction of selenocystine by TrxR (20 nM) after 15 minutes incubation with Ga; Th 
and Rf (38.5 μM) and auranofin (62.5 μM); (A) TrxR1; (B) mTrxR2 (GCUG); (C) mTrxR2 
(GCCG). The number of asterisks indicate significant differences compared with control (* p 
<0.05, ** p <0.01) 
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Table 36. Rates of of selenocystine reduction by TrxR enzymes after 15 minutes incubation with 
Ga, Rf, auranofin and Th with respect to control. NADPH consumption expressed as NADPH 
mol/min-mol enzyme 
  
TrxR1 
mTrxR2 
(GCUG) 
mTrxR2 
(GCCG) 
Control 337 ± 80.5 347 ± 21.5 82.2 ± 18.8 
Ga 331 ± 47.9 399 ± 13.9* 114 ± 43.1 
Rf 393 ± 8.70 428 ± 18.8** 98.2 ± 33.6 
Th 489 ± 36.0* 564 ± 65.3** 205 ± 34.5** 
Auranofin 15.23 ± 19.0** 1.67 ± 6.14** 8.00 ± 8.35** 
The number of asterisks indicate significant differences compared with control (* p <0.05, ** p 
<0.01) 
6.3.8 Reactivity of TrxR1 and mTrxR2 (GCUG) with substrate hydrogen peroxide in 
the presence of antibiotics  
 
In the presence of antioxidants, hydrogen peroxidase activity was not 
compromised as shown in Figure 82 and Table 37. Reduction of H2O2 requires C-
terminal Sec97-98.The result presented below shows that these antioxidants do not interact 
with Sec. 
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Figure 82. Hydrogen peroxide reduction by TrxR (50 nM) in the presence of Ga; Rf, Th and 
auranofin (38.5 μM).  (A) TrxR1; (B) mTrxR2 (CGUG). The data is expressed as NADPH 
consumption during reduction of H2O2. The number of asterisks indicate significant differences 
compared with control (* p <0.05, ** p <0.01) 
 
Table 37. Rate of H2O2 reduction by TrxR1 and mTrxR2 (GCUG) in the presence of Ga, Rf, 
auranofin and Th with respect to control. NADPH consumption expressed as NADPH mol/min-
mol enzyme       
 
  
TrxR1 
mTrxR2 
 (GCUG) 
Control 268± 18.6 317±12.0 
Ga 258 ± 14.0 320±17.5 
Rf 278± 13.5 305±41.6 
Th 378± 78.3 220±62.8 
Auranofin 16.6±13.6** 14.3 ±6.15** 
The number of asterisks indicate significant differences compared with control (* p <0.05, ** p 
<0.01) 
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significantly with their control except for auranofin which completely inhibit reduction of 
H2O2 with or without 15 minutes incubation, as shown in Figure 83 and Table 38. This 
increased activity of selenocystine reduction by TrxR in the presence of Th could be the 
possible result of increase in number of TrxR dimer. 
 
 
Figure 83. Hydrogen peroxide reduction by TrxR (50 nM) after 15 minutes incubation with Ga; 
Rf; Th and auranofin (38.5 μM).  (A) TrxR1; (B) mTrxR2 (CGUG). The data is expressed as 
NADPH consumption during reduction of H2O2 at 10 minutes. The number of asterisks indicate 
significant differences compared with control (* p <0.05, ** p <0.01) 
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Table 38. Rate of H2O2 reduction by TrxR1 and mTrxR2 (GCUG) after 15 minutes incubation 
with Ga, Rf, auranofin and Th with respect to control. NADPH consumption expressed as 
NADPH mol/min-mol enzyme       
 
  
TrxR1 
mTrxR2  
(GCUG) 
Control 185± 21.0 235±22.6 
Ga 182 ± 5.26 256±19.3 
Rf 158 ± 11.9 258±10.7 
Th 192± 26.2 389±20.8** 
Auranofin 11.1 ±10.0** 27.9 ±29.9** 
The number of asterisks indicate significant differences compared with control (* p <0.05, ** p 
<0.01) 
6.3.9 NADPH oxidase activity of TrxR enzymes in the presence of antibiotics 
 
Inhibition of TrxR at the C-terminal redox center induces NADPH oxidase 
activity. Rf enhanced NADPH oxidase activity by 7.8-fold with TrxR1, 5.2-fold with 
mTrxR2 (GCUG) and 3.9-fold with mTrxR2 (Δ8), as shown in Table 39. Th enhanced 
NADPH oxidase activity by 3.4-fold with mTrxR2 (GCUG) and 7.2-fold with mTrxR2 
(Δ8). 
Table 39. NADPH consumption by TrxR in the presence of Ga, Rf and Th. NADPH consumption 
expressed as NADPH mol/min-mol enzyme 
 
  
TrxR1 
mTrxR2 
(GCUG) 
mTrxR2 
(GCCG) 
mTrxR2 
(GSSG) 
mTrxR2 
(∆8) 
Control 1.13 ± 0.09 0.93 ± 0.14 2.04 ± 1.39 0.11 ± 0.04 0.49 ± 0.43 
Ga 1.88 ± 0.90 0.55 ± 0.28 0.68 ± 0.25 0.07 ± 0.01 0.10 ± 0.07 
Rf 8.76 ± 0.33** 4.81 ± 0.52** -1.29 ± 2.42 0.10 ± 0.07 1.94 ± 0.94** 
Th 2.88 ± 2.49 3.13 ± 0.27** 3.92 ± 2.03 2.09 ± 1.13* 3.52 ± 2.34** 
The number of asterisks indicate significant differences compared with control (* p <0.05, ** p 
<0.01) 
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6.4 Conclusion 
 Although all antibiotics tested activate DTNB reduction by TrxR1 and mTrxR2 
enzymes, DmTrxR enzymes are not affected by Th and Rf.  Failure to inhibit insulin 
reduction by TrxR1 indicates a non-covalent or reversible interaction with C-terminal 
redox center also supported by selenocystine reduction. Rf and Th induced NADPH 
oxidase activity in TrxR1, mTrxR2 (GCUG) and mTrxR2 (Δ8). Rf having a 
napthoquinone that can undergo autoxidation in the presence of metal ion135 have known 
to produce ROS such as .OH, O2-. and H2O2. Based on this fact, the NADPH oxidase 
induced by Rf on TrxR1 can be explained.  
6.5 Materials and methods  
 
Ga was purchased from TSZ Chem, Rf from MP Biomedicals and Th from 
Cayman Chemical. All assays were performed in triplicate. Results are presented as an 
average of three trials ±standard deviation. Error limits on graphs represent the standard 
deviation of three trials. 
DTNB reduction, reactivity with reduced selenocysteine, gel filtration, 
selenocystine, hydrogen peroxidase reduction and NADPH oxidase were performed 
according to procedure reported in section 3.5. 
6.5.1 Native page gel for disruption of TrxR1 dimer by Ga  
 
 TrxR1 (3.5 μL,12 μΜ) was reduced with NADPH (4.5 μL,1.34 mΜ) and 
incubated for 1 hour in the presence of Ga (2 μL,2.5 mΜ) in 0.5 M Tris-HCl pH 6.8 for. 
The control sample has equivalent volume of DMSO. The samples were analyzed by 
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native PAGE gel (10% acrylamide) in 1X Tris glycine buffer (25 mM Tris-base, 192 mM 
glycine) for 15 hours at 00C. The gel was stained with coomassie brilliant blue.  
6.5.2 TrxR1/Trx inhibition assay without hTrx-1 in presence of Ga 
 
 The assay was performed in 384 well black flat bottom plate in a final volume of 
100 μL.  Rat TrxR1 (10 μL, 1 μM, 0.2 mg/mL BSA, 50 mM Tris-Cl, 1 mM EDTA pH 
7.5) was pre-reduced with NADPH (5 μL, 5.37 mM) in the presence of Ga (10 μL, 200 
μM in 25% DMSO) final concentrations of 20 μM. After 30 minutes, human Trx-1 (10 
μL, 1 μM) was added to Ga control sample only but not for Ga without hTrx-1 sample 
and incubated for an additional 30 minutes.  Fluorescent substrate (20 μL, 0.4 mg/ml, 
eosin labeled bovine insulin) was added to the enzyme/Ga mixture (80 μL) to initiate the 
reaction. The fluorescence was monitored at λex/λem= 520nm/545 nm every 5 minutes 
for 1 hour.  
6.5.3 Reduction of DTNB by TrxR1 in the simultaneous the presence of curcumin 
and antioxidants  
 
 The assay was performed by addition of curcumin (20 µM) added first and 
incubated for 30 minutes followed by addition of testcompounds or vice versa. DTNB 
(20 µL, 10 mM) in 0.1 M sodium phosphate and 1 mM EDTA, pH 7.5 was added to 
initiate the reaction. The reduction of DTNB was monitored at 412 nm every 5 minutes 
for 1 hour. 
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Chapter 7. Summary and future direction of research work 
 
7.1 Summary of DTNB reduction  
 
 Except Man-A and deoxyman-A all other test compounds resulted in activation as 
shown in Table 40. The activation induced by test compounds on dead tail and truncated 
enzymes reveals the fact that covalent adducts at Sec or Cys is not required. 
Table 40. Summary for DTNB reduction assay with all the enzymes and test compounds 
 
TrxR1 
mTrxR2 
(GCUG) 
mTrxR2 
(GCCG) 
mTrxR2 
(GSSG) 
mTrxR2 
(Δ8) 
PbTx-3 Activate Activate Activate Activate Activate 
PbTx-2 Activate Activate Activate Activate Activate 
MC-LR Activate Activate Activate Activate Activate 
Dihydro MC-LR Activate * * * * 
Nodularin Activate # # # # 
Ga Activate # # # # 
Rf Activate Activate Activate Activate Activate 
Th Activate Activate Activate Activate Activate 
Man-A Inhibit Activate Activate Activate Activate 
Dihydroman-A Activate # # # # 
Deoxyman-A Inhibit # # # # 
# Indicate test compound have not been tested 
*Indicate no difference between control and sample  
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7.2 Summary for TrxR/Trx reduction 
 
 The reduction of insulin occurs via reduced Trx which in turn is reduced by 
reduced TrxR. When the C-terminal redox center is alkylated, this would interrupt the 
flow of electron and hence prevent the reduction of insulin, as shown by PbTx-2 and 
Man-A (Table 41). In the presence of rest of the test compounds the insulin reduction is 
not interrupted which would imply that these compounds are interacting non-covalently 
or reversibly with C-terminal redox center. 
Table 41. Summary for TrxR/Trx reduction with all the enzymes and test compounds 
 
TrxR1 
mTrxR2 
 (GCUG) 
PbTx-3 * # 
PbTx-2 Inhibit # 
MC-LR * # 
Dihydro MC-LR * # 
Nodularin # # 
Ga * # 
Rf * # 
Th * # 
Man-A Inhibit Inhibit 
# Indicate test compound have not been tested 
 *Indicate no difference between control and sample    
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7.3 Summary of selenocystine reduction 
 
 The reduction of selenocystine requires the C-terminal Sec/Cys, Sec being more 
efficient than Cys. The pre-incubation of Man-A with reduced TrxR1 and mTrxR2 
(GCCG) resulted in inhibition of selenocystine reduction (Table 42). Reaction of Man-A 
with TrxR1 is time dependent and the results indicate the initial alkylation at Cys 
followed by covalent adduct at Sec (also proved by gel filtration chromatography). On 
the other hand, Man-A activates slenocystine reduction of mTrxR2 (GCUG). Such 
activation can also be observed with other test compounds revealing the non-covalent 
interaction at Cys. 
 When the test compounds were not pre-incubated, most of the test compounds 
activate the selenocystine reduction (Table 42) which could be possible when the Cys of 
TrxR is adducted leaving the Sec to reduce selenocystine. The activation observed in the 
presence of test compounds also directs the possibility of selenocystine to be reduced by 
N-terminal. MC-LR is the only one compounds that inhibit the reduction of selenocystine 
indicating the interaction at C-terminal Sec.   
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Table 42. Summary of selenocystine reduction with and without pre-incubation    
      
 
Pre-incubation No pre-incubation 
TrxR1 
mTrxR2 
(GCUG) 
mTrxR2 
(GCCG) TrxR1 
mTrxR2 
(GCUG) 
mTrxR2 
(GCCG) 
PbTx-2 * Activate Activate * * * 
MC-LR * Inhibit * * Inhibit * 
Ga * Activate * * Activate * 
Rf * Activate * * Activate Activate 
Th Activate Activate Activate * * Activate 
Man-A Inhibit Activate Inhibit Activate Activate * 
     *Indicate no difference between control and sample  
7.4 Summary of H2O2 reduction 
 
 The reduction of H2O2 absolutely requires the presence of C-terminal Sec. In the 
presence of Man-A, the reduction of H2O2 by TrxR1 and mTrxR2 (GCUG) is prevented 
when not pre-incubated (Table 43). Interaction of Man-A with Cys of TrxR could prevent 
the reduction of oxidized Sec (SeOH) and result in inhibition. The pre-incubation of 
Man-A with reduced TrxR alkylates the Sec (also proved by prevention of selenocystine 
reduction in the presence of Man-A). 
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               Table 43. Summary of H2O2 reduction with and without pre-incubation   
  
 
Pre-incubation     No pre-incubation 
TrxR1 
mTrxR2 
(GCUG) TrxR1 
mTrxR2 
(GCUG) 
PbTx-2 Inhibit Activate * Inhibit 
MC-LR * Activate * * 
Ga  *  * *  * 
Rf * * * * 
Th  * Activate * * 
Man-A Inhibit Inhibit Inhibit Inhibit 
 *Indicate no difference between control and sample  
7.5 Summary of NADPH oxidase activity 
 
 Man-A induced NADPH oxidase activity with all the enzymes (Table 44). It is 
known that Man-A inhibit Sec of TrxR which induce production of O2-. by forming 
SecTRAP. The dead tail and truncated enzyme also consumed more NADPH in the 
presence of Man-A as well as Rf, Th and PbTx-2. This fact suggests that alkylation at Sec 
is not required for activation of NADPH consumption. 
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Table 44. Summary of NADPH oxidase activity 
 
TrxR1 
mTrxR2 
(GCUG) 
mTrxR2 
(GCCG) 
mTrxR2 
(GSSG) 
mTrxR2 
(Δ8) 
PbTx-3 # * # # * 
PbTx-2 * * * Activate Activate 
MC-LR * * * * * 
Ga * * * # * 
Rf Activate Activate * * Activate 
Th * Activate * * Activate 
Man-A Activate Activate Activate Activate Activate 
# Indicate test compound have not been tested 
*Indicate no difference between control and sample 
 The test compounds were selected because of their similar size and molecular 
weight and electrophilic functional groups. All of the test compounds activate DTNB 
reduction by TrxR1 and mTrxR2 to different degrees except Man-A which inhibits 
TrxR1. Man-A acts by activating DTNB reduction by mTrxR2. TrxR1 and mTrxR2 
enzymes are isoforms and have similar mechanism of reducing substrates. All the above 
results, it can be concluded that Man-A reacts with both C-terminal Cys/Sec. The reaction 
of Man-A with Sec is time dependent and covalent, possibly forms Michael adduct, as 
represented by path A in Figure 84. On the other hand, the reaction with Cys is reversible 
and takes place instantaneously as represented by path B in Figure 84. Most of the other 
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test compounds also react in similar way. Additional experiments are required to 
understand the underlying mechanism to prove the above stated hypothesis.  
                                   
               Figure 84.  Hypothesized mechanism of interaction of test compounds with TrxR 
7.6 Future direction 
 
7.6.1 Evaluation of disruption of TrxR multimers 
 
 It still remains unclear the reason behind activation of DTNB reduction by TrxR 
in the presence of test compounds. We tried to reason if the increase in TrxR1 activity is 
due to disruption of TrxR1 dimer in the presence of Ga (presented in section 6.3.6) but 
did not observe as expected. Acetylation of Lys residue of TrxR1 increased the enzyme 
activity by destabilizing low activity multimers140. It could be possible that these test 
compounds may act in a similar manner by disrupting the TrxR multimers. This can be 
achieved by separating low activity tetramers of TrxR by passing through size exclusion 
chromatography. The quantification of active dimers can be then achieved by western 
blot technique. 
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7.6.2 Irreversible inhibition of TrxR by test compounds 
 
 The gel filtration chromatography experiment is inconclusive as these 
experiments are performed at very low concentration of 4.2 μΜ compared to 20 μΜ for 
DTNB reduction assay. Hence gel filtration experiment should be performed at 20 μΜ 
concentration. If the interaction of test compounds with TrxR is covalent then similar fold 
of activation should be observed in the sample incubated with test compounds after 
passing through size exclusion column in DTNB reduction.  
7.6.3 Mass spectroscopy approach to identify the adduct  
  
Our approach to identify the PbTx-2 + TrxR1 adduct was inconclusive as PbTx-2 being a 
large polyether compound forbid to ionize and hence was not observed in mass 
spectrometry. Alternatively, MC-LR being a peptide TrxR + MC-LR adduct could be 
observed in mass spectroscopy. Another alternative is to study X-ray crystal the test 
compound and TrxR.  
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